



LUND UNIVERSITY

Non-invasive Rejection Surveillance after Heart Transplantation

Sukma Dewi, Ihdina

2017

Document Version:

Publisher's PDF, also known as Version of record

[Link to publication](#)

Citation for published version (APA):

Sukma Dewi, I. (2017). *Non-invasive Rejection Surveillance after Heart Transplantation*. Lund University: Faculty of Medicine.

Total number of authors:

1

General rights

Unless other specific re-use rights are stated the following general rights apply:

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117
221 00 Lund
+46 46-222 00 00

Non-invasive Rejection Surveillance after Heart Transplantation

Ihdina Sukma Dewi

Department of Cardiology
Lund University, Lund, Sweden



LUND
UNIVERSITY

DOCTORAL DISSERTATION

By due permission of the Faculty of Medicine, Lund University, Sweden,
will be publicly defended at Segerfalksalen, Biomedical Center, BMC A10
2017-03-24 at 13.00

Faculty opponent

Professor Ebo De Muinck, MD, PhD
Department of Cardiology, Linköping University

Organization LUND UNIVERSITY Division of Cardiology Department of Clinical Science Biomedical Centre, D12 221 84 Lund, Sweden		Document name DOCTORAL DISSERTATION	
		Date of issue 24 th of March, 2017	
Author: Ihdina Sukma Dewi		Sponsoring organization	
Title and subtitle: Non-invasive Rejection Surveillance after Heart Transplantation			
<p>Abstract</p> <p>Heart transplantation is a life-saving therapy for patients with end-stage heart failure. Despite excellent outcomes, mainly due to life-long treatment with a cocktail of immunosuppressants, acute cellular rejection (ACR) remains an impending threat in heart transplant patients. Endomyocardial biopsy, a gold standard used in the clinic for ACR diagnosis and surveillance, is associated with risks due to its invasiveness, subjectivity and expense. Moreover, many rejection events on the molecular level could provide early diagnosis, before rejection is seen histologically. The development of molecular biomarkers for the non-invasive diagnosis and surveillance of allograft rejection post-transplantation has been a long-standing challenge in heart transplantation.</p> <p>The profiling of circulating microRNAs in the serum of heart transplant patients provided evidence that changes in these profiles could be used to discriminate between organ rejection and quiescence. MiR-142-3p, which had the best diagnostic ability among the microRNAs tested in the heart transplantation cohort, was enriched in both the serum exosomes and in exosomes shed during <i>ex vivo</i> T cell activation. MiR-142-3p takes part in intercellular communication between T cells and endothelial cells by regulating the expression of RAB11FIP2 in endothelial cells, and promoting changes in endothelial physiology by impairing vascular integrity - a molecular hallmark of inflammation, including graft rejection.</p> <p>By performing proteomic profiling, it was demonstrated that inflammatory fingerprints consisting of T-lymphocyte chemokines and cytokines were increased in the serum of heart transplant patients with ACR, and could provide good diagnostic discrimination of rejection.</p> <p>In conclusion, this thesis provides evidence of the possibility of using transcriptomic and proteomic strategies for non-invasive diagnosis and surveillance of allograft rejection after heart transplantation. Moreover, the work presented in this thesis has also shed new light on the interaction between the host immune system and the cardiac allograft endothelium during ACR, which could be used as the basis for the development of microRNA-based therapy.</p>			
Key words: Heart transplantation, Acute cellular rejection, Non-invasive monitoring, microRNAs, microRNA biomarker, T cells, Proteomic biomarker.			
Classification system and/or index terms (if any)			
Supplementary bibliographical information		Language: English	
ISSN and key title 1652-8220 Lund University, Faculty of Medicine Doctoral Dissertation Series 2017:45		ISBN 978-91-7619-425-6	
Recipient's notes	Number of pages	Price	
	Security classification		

I, the undersigned, being the copyright owner of the abstract of the above-mentioned dissertation, hereby grant to all reference sources permission to publish and disseminate the abstract of the above-mentioned dissertation.

Signature _____ Date _____

Non-invasive Rejection Surveillance after Heart Transplantation

Ihdina Sukma Dewi

Department of Cardiology
Lund University, Lund, Sweden



LUND
UNIVERSITY

Cover Image: Molecular facet of donor heart. The image was created using Photo Lab Picture Editor FX.

© Ihdina Sukma Dewi

Department of Cardiology,
Clinical Sciences, Lund,
Faculty of Medicine
Lund University
Lund
Sweden

ISSN 1652-8220

ISBN 978-91-7619-425-6

Lund University, Faculty of Medicine Doctoral Dissertation Series 2017:45

Printed in Sweden by Media-Tryck, Lund University
Lund 2017



To Mika
My little heart-warrior

&

Rayan
My day-to-day muse

“Some people never meet their heroes - I gave birth to mine”



“To improve is to change; to be perfect is to change often.”

(Winston Churchill)

Content

List of Papers	11
Abbreviations	12
Abstract.....	13
Popularized Summary	14
Populärvetenskaplig Sammanfattning	16
Introduction.....	19
Heart Transplantation	19
Heart Transplantation in Scandinavia.....	19
Acute Cellular Rejection	21
Immunology of Transplant Rejection.....	21
Monitoring of Acute Cellular Rejection	23
Non-invasive Rejection Surveillance Strategies	24
Functional Assay	25
mRNA Profiling.....	26
cfdDNA Profiling	26
microRNA Profiling	27
Proximity Extension Assay.....	27
MicroRNA Biomarkers	28
MicroRNAs in Liquid Biopsies	29
Intercellular Communication via microRNA Transport.....	29
Role of microRNA in Organ Transplantation.....	31
Aims and Hypotheses	33
Materials and Methods.....	35
Heart Transplant Patients (Papers I, II, III and IV)	35
Subjects.....	35
Blood Collection (Papers I, II, III and IV).....	36
RNA Purification from Serum (Papers I and II).....	37
RNA Purification from Serum Exosomes (Paper III).....	37
First-strand cDNA Synthesis	37
MicroRNA Profiling Assay (Paper I and Paper III)	38
Validation of Selected microRNAs (Paper I and II).....	38

Proteomic Profiling (Paper IV).....	39
<i>In Vitro</i> and <i>Ex Vivo</i> Cultures (Paper III).....	40
Isolation of Human PBMCs and T cells	40
<i>Ex vivo</i> Activation of Human T cells.....	40
Exosome Isolation	40
MicroRNA Transfer between T cells and Endothelial Cells	41
Microarray of Endothelial cells	41
Transfection of Endothelial Cells	41
3'UTR Target Plasmid Reporter Assay	42
Vascular Permeability Assay	43
Statistical Analysis (Paper I - IV).....	43
Results.....	45
Study I	45
Study II	47
Study III.....	52
Study IV.....	57
Discussion.....	61
Non-invasive Rejection Surveillance – An Unmet Need	61
Early Detection of ACR – Genomic Signatures	62
Circulating microRNAs as Non-invasive Biomarkers	64
Technical Considerations.....	65
Intercellular Transport of Functional microRNAs	66
Endothelial and T cells "Small Talk" via Exosomes during ACR.....	67
MicroRNAs as Therapeutic Targets.....	68
Serum Protein Biomarkers – Tackling the Challenges.....	68
Conclusions.....	71
Acknowledgement	73
References.....	77

List of Papers

This thesis is based on the following papers, which will be referred to in the text by their roman numerals:

- I. **Sukma Dewi I**, Torngren K, Gidlof O, Kornhall B, Ohman J. Altered serum miRNA profiles during acute rejection after heart transplantation: potential for non-invasive allograft surveillance. *The Journal of heart and lung transplantation*. Apr 2013;32(4):463-466.
- II. **Sukma Dewi I**, Hollander Z, Lam KK, McManus JW, Tebbutt SJ, Ng RT, Keown PA, McMaster RW, McManus BM, Gidlöf O, Öhman J. Association of Serum MiR-142-3p and MiR-101-3p Levels with Acute Cellular Rejection after Heart Transplantation. *PloS One*. 2017;12(1):e0170842.
- III. **Sukma Dewi I**, Celik S, Karlsson A, Hollander Z, Lam K, McManus JW, Tebbutt S, Ng R, Keown P, McMaster R, McManus B, Öhman J, Gidlöf O. Exosomal miR-142-3p is increased during cardiac allograft rejection and augments vascular permeability through down-regulation of endothelial RAB11FIP2 expression. *Cardiovascular research*. Jan 10 2017. pii: cvw244.
- IV. **Sukma Dewi I**, Gidlof O, Holander Z, Lam K, McManus J, Tebbutt S, Ng R, Keown P, McMaster R, Ohman J, McManus B, Smith JG. Immunologic serum protein profiles for non-invasive detection of acute cellular rejection in cardiac allograft patients. *Manuscript*.

Abbreviations

ACR	Acute Cellular Rejection
AUC	Area Under the Curve
CARGO	Cardiac Allograft Rejection Gene-expression Observational
CRP	C-reactive protein
EVs	Extracellular Vesicles
FDR	False Discovery Rate
HLA	Human Leukocyte Antigen
HUVECs	Human Umbilical Vein Endothelial Cells
IMAGE	Invasive Monitoring Attenuation through Gene Expression
ISHLT	International Society for Heart and Lung Transplantation
MHC	Major Histocompatibility Complex
miR	microRNA
qRT-PCR	Quantitative Reverse Transcription PCR
PBMC	Peripheral Blood Mononuclear Cells
PCR	Polymerase Chain Reaction
PEA	Proximity Extension Assay
PHA	Phytohemagglutinin
RAB11FIP2	RAB11 Family Interacting Protein 2
RNA	Ribonucleic Acid
ROC	Receiver Operating Characteristic
SAM	Significance Analysis of Microarrays

Abstract

Heart transplantation is a life-saving therapy for patients with end-stage heart failure. Despite excellent outcomes, mainly due to life-long treatment with a cocktail of immunosuppressants, acute cellular rejection (ACR) remains an impending threat in heart transplant patients. Endomyocardial biopsy, a gold standard used in the clinic for ACR diagnosis and surveillance, is associated with risks due to its invasiveness, subjectivity and expense. Moreover, many rejection events on the molecular level could provide early diagnosis, before rejection is seen histologically. The development of molecular biomarkers for the non-invasive diagnosis and surveillance of allograft rejection post-transplantation has been a long-standing challenge in heart transplantation

The profiling of circulating microRNAs in the serum of heart transplant patients provided evidence that changes in these profiles could be used to discriminate between organ rejection and quiescence. MiR-142-3p, which had the best diagnostic ability among the microRNAs tested in the heart transplantation cohort, was enriched in both the serum exosomes and in exosomes shed during *ex vivo* T cell activation. MiR-142-3p takes part in intercellular communication between T cells and endothelial cells by regulating the expression of RAB11FIP2 in endothelial cells, and promoting changes in endothelial physiology by impairing vascular integrity - a molecular hallmark of inflammation, including graft rejection.

By performing proteomic profiling, it was demonstrated that inflammatory fingerprints consisting of T-lymphocyte chemokines and cytokines were increased in the serum of heart transplant patients with ACR, and could provide good diagnostic discrimination of rejection.

In conclusion, this thesis provides evidence of the possibility of using transcriptomic and proteomic strategies for non-invasive diagnosis and surveillance of allograft rejection after heart transplantation. Moreover, the work presented in this thesis has also shed new light on the interaction between the host immune system and the cardiac allograft endothelium during ACR, which could be used as the basis for the development of microRNA-based therapy.

Popularized Summary

Heart transplantation is a life saving treatment for adults and children with end-stage heart failure. Since the first heart transplantation performed in 1967, advances in perioperative care, surgical techniques and immunosuppressive medications have considerably improved post-transplant outcome. Nowadays, adult recipients can expect a median heart transplant survival of more than 10 years and infant recipient can expect a median heart transplant survival that is more than 20 years. However, organ rejection remains a major issue after heart transplantation that lead to the loss of the transplanted organ and morbidity.

Acute cellular rejection (ACR) is the most common form of organ rejection after heart transplantation that is experienced by 20% to 50% of patients at least once during the first year post-transplantation, despite the presence of immunosuppressive medications. The risk of ACR is highest in the first 6 month after heart transplantation. To monitor ACR, an invasive technique called endomyocardial biopsy, where a small sample from heart muscles is taken by using catheter introduced through the vein in the neck or in the thigh, is frequently performed on the patients after heart transplantation. Endomyocardial biopsy is not only invasive, but it is also subjective and expensive. Therefore, developing biomarkers from the peripheral blood that can be used to diagnose ACR from a simple blood test is required in clinical practice.

In Study I, we performed a pilot study, where we performed microRNA profiling in the blood samples of heart transplant recipients with ACR. MicroRNAs are small, single stranded RNA transcripts that are involved in many physiological and disease processes in the human body. Changes in the microRNA profile in tissue or in the peripheral blood have been used earlier as a novel strategy in the biomarker research field. We demonstrated in this study the possibility to use respective strategy to discriminate between heart transplantation patients with ACR and those without.

In Study II, we validated the findings of Study I in a larger group of heart transplant patients. MiR-142-3p and miR-101-3p had the best diagnostic performance among seven microRNAs tested that could discriminate between patients with and without rejection. Moreover, the performance miR-142-3p and miR-101-3p were independent of following important clinical parameters; calcineurin inhibitor levels, kidney function, and general inflammation state.

In Study III, we focused our study in miR-142-3p that was observed in Studies I and II, to be higher in the peripheral blood of ACR patients compared to non-rejection patients. We hypothesized that the presence of miR-142-3p in the peripheral blood during ACR associated with the disease process involving T cells

and endothelial cells, 2 cell populations known for their important roles in orchestrating ACR. We identified in this study the novel mechanism of communication between immune cells and endothelial cells, where miR-142-3p shed by T cells during immune activation or ACR convey a message to endothelial cells resulted in a physiological change in endothelial cells that fit the essential process of ACR.

In Study IV, we demonstrated that proteomic profiling approach employing a cutting-edge technique to find blood-borne protein biomarkers with high sensitivity and high specificity could be used as a new strategy for non-invasive ACR monitoring in heart transplant patients.

In conclusion, this thesis provides evidence of the possibility of using transcriptomic (microRNA) and proteomic (inflammatory proteins) strategies for non-invasive diagnosis and surveillance of allograft rejection after heart transplantation. Moreover, the work presented in this thesis has also shed new light on the interaction between the host immune system and the donor heart endothelium during ACR, which could be used as the basis for the development of microRNA-based therapy.

Populärvetenskaplig Sammanfattning

Hjärttransplantation är i nuläget den enda livräddande behandling som finns för vuxna och barn med grav hjärtsvikt. Sedan den första hjärttransplantation utfördes 1967 har framsteg inom perioperativ vård, kirurgiska tekniker och immunosuppressiva läkemedel lett till en avsevärd förbättring av mortalitet och livskvalitet hos transplanterade patienter. Förväntad livslängd efter hjärttransplantation är idag ca 10 år för vuxna och ca 20 år för spädbarn. Trots immunosuppressiv behandling är organavstötning, vilket kan leda till förlust av det transplanterade organet, fortfarande ett stort problem efter hjärttransplantation.

Akut cellulär avstötning (ACA) är den vanligaste typen av organavstötning efter hjärttransplantation och drabbar 20% till 50% av patienterna minst en gång under det första året efter transplantation trots behandling med immunosuppressiva läkemedel. Risken för ACA är högst under de första sex månaderna efter hjärttransplantation. För att övervaka ACA används en invasiv teknik som kallas endomyokardiell biopsi, där ett litet prov från hjärtmuskeln tas med hjälp av en kateter införd genom en ven i halsen eller i låret. Endomyokardbiopsi har, förutom att det är ett invasivt ingrepp, också andra nackdelar. Bedömningen av biopsin är subjektiv, proceduren är kostsam och innebär inte minst ett obehag för patienten. Att hitta andra, icke-invasiva sätt att diagnostisera avstötning med hjälp av ett enkelt blodprov skulle därför vara till stor nytta för patienter efter hjärttransplantation. Syftet med denna avhandling var att hitta s.k. biomarkörer, d.v.s. ämnen i blodet som kan användas för att diagnostisera avstötning, samt att undersöka några av de biologiska mekanismer som initierar avstötningsprocessen.

I det första delarbetet utförde vi en pilotstudie, där vi undersökte mikroRNA-profilen i blodprover från hjärttransplanterade patienter med ACA. MikroRNA är små RNA-transkript som är involverade i många fysiologiska och patologiska processer i människokroppen. Förändringar i mikroRNA-profil i vävnad eller i cirkulationen har nyligen använts som en strategi för att hitta nya biomarkörer för andra sjukdomstillstånd. Vi visade i denna studie möjligheten att använda denna strategi för att kunna identifiera patienter med ACA.

I avhandlingens andra delarbete validerade vi resultaten av Studie I i en större grupp av hjärttransplantationspatienter. miR-142-3p och miR-101-3p uppvisade de bästa diagnostiska egenskaperna bland de sju mikroRNA som testades och kunde användas för att särskilja patienter med och utan avstötning. Nivåerna av miR-142-3p och miR-101-3p var oberoende av flertalet viktiga kliniska parametrar, bland annat njurfunktion, inflammationsnivå och mängden immunosuppressiva läkemedel i blodet.

I det tredje delarbetet fokuserade vi på miR-142-3p, som i studie I och II visade sig ha förhöjda nivåer i blodet hos patienter med ACA. Vår hypotes var att miR-142-3p spelar roll för sjukdomsprocessen genom att fungera som en signalmolekyl mellan kroppens immunförsvar och det transplanterade organet. Vi identifierade i denna studie en ny mekanism där miR-142-3p frisätts från T-celler under immunaktivering och vid ACR, och kan påverka endotelcellerna i kärlväggen hos det transplanterade hjärtat, vilket i sin tur skulle kunna bidra till att påskynda avstötningsprocessen.

I det fjärde delarbetet använde vi avancerad proteomik för att hitta cirkulerande biomarkörer med hög sensitivitet och specificitet för ACA. Resultaten visade att nivåerna av proteinerna SLAMF1 och CXCL10 kunde användas för att identifiera patienter med avstötning.

Sammanfattningsvis är min förhoppning att denna avhandling kan öppna möjligheten att använda mikroRNA och inflammatoriska proteiner för icke-invasiv diagnostik och övervakning av organavstötning efter hjärttransplantation. Dessutom har arbetet med denna avhandling ökat förståelsen för hur kommunikationen mellan patientens immunsystem och det transplanterade hjärtats endotel fungerar under avstötningsprocessen.

Introduction

Heart Transplantation

The world's first human heart transplantation was performed at Groote Schuur Hospital in Cape Town, South Africa, in the early morning of Sunday, December 3rd, 1967, led by a South African surgeon Dr Christian Barnard, who transplanted a donor heart into a 57-year-old patient suffering from ischaemic heart disease^{1,2}. Despite initial success, heart transplantation did not gain overall acceptance among healthcare practitioners³. The life-saving intervention of heart transplantation in patients with end-stage heart failure was mainly hampered by post-transplantation complications, including allograft rejection, and a high risk of infection resulting from high doses of nonspecific immunosuppressive drugs.

Heart transplantation became the treatment of choice for patients with end-stage heart failure in the early 1980s, when cyclosporine A started to be widely used as an immunosuppressant drug in heart transplant recipients, leading to a substantial improvement in patient survival^{4,5}. Since then, over 100,000 heart transplants have been performed worldwide, for the treatment of primary heart diseases including congenital, non-ischaemic, ischaemic and valvular cardiomyopathy, to improve survival and enhance quality of life^{6,7}. One-year survival following heart transplantation has improved from 30% in the first era, when heart transplantation was first introduced, to a remarkable number of 90% in the current era⁸.

Heart Transplantation in Scandinavia

The first heart transplantation programme in Scandinavia was initiated in Oslo, Norway, in 1983, and was soon followed by programmes in the other Scandinavian countries. The first heart transplantations in Sweden were performed at Sahlgrenska University Hospital in Gothenburg, in 1984, and at Lund University Hospital in 1988. About 50 heart transplantations take place each year in both Lund and Gothenburg, the only two centres in Sweden currently performing heart transplantation.

The Scandinavian countries have 25 million inhabitants, and to improve collaboration among Scandinavian transplant centres, Norway, Sweden, Finland,

Denmark and Iceland share a common database regarding organ allocation within the Nordic organ exchange organization, Scandiatransplant. This means that all Scandinavian patients waiting for a new organ are listed in one common database, which increases accessibility to organ transplantation, as well as ensuring the optimal use of available organs^{9,10}.

The Nordic Thoracic Transplant Study Group (NTTSG) created a registry within the Scandiatransplant organization, integrating all thoracic transplantations, including heart transplantations, performed in Scandinavia. All transplantation centres participating in the NTTSG, i.e. Aarhus, Copenhagen, Gothenburg, Helsinki, Lund, Oslo and Stockholm, report their data to the NTTSG, and these are subsequently reported to the International Society for Heart and Lung Transplantation (ISHLT) on a yearly basis.

According to NTTSG data for 2015, more than 3000 heart transplantations have been performed in Scandinavia, with relatively good overall survival, in line with the ISHLT registry. The median survival for the whole cohort in the NTTSG 2015 registry was 14.5 years, compared to 10.3 years in the ISHLT registry (Figure 1)¹¹.




Figure 1. Actual Survival after heart transplantation in Scandinavia 2015. Reprinted with permission from Scandiatransplant.

Acute Cellular Rejection

Acute cellular rejection (ACR), graft failure, cardiac allograft vasculopathy, infection, renal failure and malignancy remain the leading causes of mortality after heart transplantation^{8,12}. ACR is experienced by 20% to 50% of patients at least once during the first year post-transplantation, despite of the presence of immunosuppressant¹³. Allograft rejection has been of paramount interest since the first heart transplantation was performed. In a letter to Dr Christian Barnard exhibited in the Heart of Cape Town Museum, praising the world's first human heart transplantation, Dr Norman Shumway, a Stanford cardiac surgeon who performed the first successful human transplantation in the USA, suggested an early biomarker of cardiac allograft rejection. In his letter, dated December 4th 1967, he wrote, "Be certain to watch the R-wave of the ECG during the next several weeks for indices of rejection. It appears to be the earliest herald of important graft invasion." Since 1967, considerable efforts have been made to advance the precision of acute cardiac allograft rejection diagnosis.

Immunology of Transplant Rejection

Rejection is caused by the immune response of the host to donor antigens that are considered to be "non-self"; this recognition of "foreign" antigens is called allorecognition. The most prominent response of alloantigen mediated by host T cells, which recognize the major histocompatibility complex (MHC), an antigen expressed on the surface of donor cells. MHC in graft rejection was first demonstrated in mice and the World Health Organization Nomenclature Committee designated that the leukocyte antigens controlled by the closely linked genes of the human MHC be named human leukocyte antigen (HLA)¹⁴.

Based on the time of onset, rejection can be divided into three general types: hyperacute, acute and chronic rejection. Hyperacute rejection occurs within minutes to hours after transplantation, and is caused by a mismatch of host and donor antigens. However, this type of rejection is very rare, due to advances in knowledge on transplant immunology and pre-transplantation assessment of the immune compatibility of the donor and the recipient, including HLA matching, a crossmatching method that can detect preformed antidonor antibodies, and ABO blood type matching. Acute rejection occurs within days or weeks after transplantation and is mediated by either antibodies (less common) or T cells (most common). In contrast to hyperacute and acute rejection, chronic rejection occurs months to years after transplantation, and is mainly due to the insufficiency of immunosuppression medication.

T cells and endothelial cells play essential roles in the initial events of ACR pathophysiology^{15,16}, mainly due to their unique locations, which enable direct contact between the endothelial cell lining of the graft vessel and host T cells^{17,18}. Endothelial cells initiate rejection by presenting alloantigen to circulating T cells¹⁷. Allorecognition is then mediated by activated host T cells via two distinct pathways: the direct and the indirect pathways¹⁸. In the direct allorecognition pathway, T cells recognize intact MHC molecules displayed on the surface of the donor cells. In the indirect allorecognition pathway, T cells recognize the processed donor MHC molecules presented as peptides by self-MHC molecules on the surface of the recipient's antigen presenting cells (APC)¹⁹⁻²² (Figure 2).

The subsequent events in ACR that lead to the advancement of tissue damage and allograft destruction are also mainly elicited by the interactions between T cells and endothelial cells^{23,24}. The recruitment of activated T cells into the graft requires a multi-step process orchestrated by the interplay between endothelial cells and T cells in each of the steps²⁵. Moreover, human endothelial cells have also been implicated in modulating T cell subsets, for example, Th17, an Achilles heel in immunosuppression that can mediate proinflammatory immune response, which accelerates allograft rejection, and regulatory T cells, which are important regulators of immune homeostasis in transplantation²⁶.




Figure 2. T cell-mediated allograft rejection via the direct and indirect pathways. (Reprinted with permission from Nature Publishing Group. Briscoe DM, et al. A rendezvous before rejection: where do T cells meet transplant antigens? Nature medicine. Mar 2002;8(3):220-222.)

Monitoring of Acute Cellular Rejection

Endomyocardial biopsy or right-heart catheterization remains the gold standard for the diagnosis and rejection surveillance in heart transplant recipient^{12,27-29}. Typical surveillance biopsy protocol at heart transplantation centres is once weekly for the first month after transplantation, every 2 weeks in the second month, once monthly between 3 and 6 months and every 2 months between 6 and 12 months. The myocardial tissue is sampled from the right ventricular septal wall using a biptome introduced through either the jugular or femoral vein using fluoroscopy or 2-dimensional echocardiography to provide information on the course of the biptome and the site of the biopsy³⁰⁻³³. The presence of massive inflammatory infiltration of lymphocytes in the myocardium is the histological hallmark of ACR^{34,35}.

The ISHLT 2004 guidelines for cardiac allograft biopsy grading are used to diagnose ACR³⁴(Figure 3). This grading system is a revision of the 1990 ISHLT grading system. The revised (R) categories of cellular rejection are as follows: Grade 0R - no rejection (no change from 1990); Grade 1R - mild rejection (1990 Grades 1A, 1B and 2); Grade 2R - moderate rejection (1990 Grade 3A); and Grade 3R - severe rejection (1990 Grades 3B and 4).




Figure 3. International Society for Heart and Lung Transplantation 2004 grading system for cardiac allograft biopsy. (Reprinted with permission from Elsevier. Stewart S, *et al.* Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. *The Journal of heart and lung transplantation*. Nov 2005;24(11):1710-1720.)

However, despite its high sensitivity and specificity as the primary monitoring modality for the diagnosis of acute cellular rejection³⁶, endomyocardial biopsy suffers from several drawbacks. The main problems associated with endomyocardial biopsy lie in its subjectivity, including sampling error, false-negative results and inter-observer variability with the overall, all-grade agreement between pathologists being only 71%³⁷⁻⁴⁰.

Furthermore, endomyocardial biopsy may expose heart transplant patients to discomfort or risks, due to the invasive nature of the technique. There are low but finite risks of morbidity, including arrhythmia and tricuspid regurgitation, as well as myocardial perforation and mortality^{27,41-43}. As a result of these risks, the use of endomyocardial biopsy as a cornerstone of the diagnosis and surveillance of acute cellular rejection after heart transplantation has recently come into question. A complementary or replacement surveillance method, preferably a non-invasive one, remains an unmet need in the field of solid organ transplantation.

Non-invasive Rejection Surveillance Strategies

The invasiveness and associated drawbacks of endomyocardial biopsy have led to the search for alternative, non-invasive methods for the diagnosis and surveillance of allograft rejection, for use in routine clinical care. Several non-invasive techniques have been demonstrated, including imaging techniques, such as echocardiography⁴⁴⁻⁴⁶ and cardiovascular magnetic resonance^{47,48}, as well as cardiovascular electrophysiological monitoring^{49,50}.

Research is also being carried out to identify a suitable biomarker in peripheral blood. So far, biomarkers of ACR in peripheral blood have been the most commonly investigated, and there is considerable interest in this field, mainly because peripheral blood is an easily accessible source of patient material, and a wide range of techniques can be used to detect blood-borne biomarkers that can accurately reflect the recipient's immune response to the cardiac allograft (Figure 4). Moreover, a vast clinical diagnostic infrastructure is widely available for the analysis of blood samples, indicating that peripheral blood will remain the preferred diagnostic specimen in the foreseeable future.




Figure 4. Techniques that have been used to detect biomarkers in the peripheral blood of heart transplant recipients.

Functional Assay

The function of lymphocytes can be determined *ex vivo* by their proliferation ability or by their intracellular adenosine triphosphate (iATP) concentration after phytohaemagglutinin (PHA) stimulation. Both assays can provide information on the status of the cell-mediated immune response in immunosuppressed patients. Studies using the iATP assay in kidney, liver and heart transplantation patients have shown that high CD4+ T cell iATP concentration is associated with a risk of ACR, and that low concentration is associated with the risk of infection⁵¹⁻⁵⁵. The iATP assay has received approval from the US Food and Drug Administration (FDA), and is available commercially as the ImmuKnow assay (Cylex, Columbia, MD, USA).

However, there are some major concerns associated with the implementation of this approach for the diagnosis of ACR, including questions regarding sensitivity and specificity. The ImmuKnow assay mainly gives an indication of the patient's general immune status, not specifically T cell reactivity directed towards the allograft. Furthermore, there is some evidence of inconsistencies in the interpretation of the results when using this technique⁵⁶⁻⁵⁹.

mRNA Profiling

Gene expression profiling is being performed in the search for peripheral blood biomarkers using a microarray technique that enables broad gene screening and techniques based on the real-time polymerase chain reaction (qRT-PCR) for hypothesis-driven investigations.

Horwitz et al. conducted a case-control study using microarray analysis of the whole blood in a cohort of 189 cardiac transplant patients, and demonstrated that gene transcripts in the expression profile of peripheral blood were correlated with histologically verified ACR⁶⁰. In a multicentre Cardiac Allograft Rejection Gene expression Observational (CARGO) study, a development study designed to test the gene expression profiling hypothesis, Deng et al. developed an algorithm to generate a score ranging from 0 to 40 providing a measure of the expression of 20 genes (11 informative, 9 control and normalization) in peripheral blood mononuclear cells (PBMCs) using qRT-PCR⁶¹. Lower scores were found to be associated with a very low likelihood of moderate/severe ACR⁶². This gene-expression profiling algorithm has been approved by the FDA, and is commercially available as AlloMap (CareDX, Brisbane, CA, USA).

In the 2010 ISHLT Guidelines for the Care of Heart Transplant Recipients, AlloMap was assigned a Class IIa recommendation Level of evidence B, stating that: “it can be used to rule out the presence of \geq grade 2R acute cellular rejection in appropriate low-risk patients, between 6 months and 5 years after transplantation”¹². Although results have been very promising, the study design of the clinical trial of AlloMap, known as the Invasive Monitoring Attenuation through Gene Expression (IMAGE) trial, displayed an essential limitation, as patients who had undergone transplantation less than 6 months previously were not included in the trial, and 85% of the study population was made up of patients who had undergone transplantation between 1 and 5 years previously⁶³, the period when the overall risk of rejection is low⁶⁴.

cfDNA Profiling

Cell-free DNA (cfDNA) is a short length of double-stranded DNA released from tissues as a result of either normal physiological cell turnover or pathological apoptosis. This cfDNA is found in the circulation at levels typically around 3 ng/mL, and has been used for years for non-invasive prenatal testing of foetal DNA to screen for genetic abnormalities^{65,66}.

In the field of solid organ transplantation, cell-free donor DNA (cfDNA) was first detected in recipients of sex-mismatched grafts⁶⁷. Subsequent studies confirmed the hypothesis that cfDNA is associated with graft rejection^{68,69}. A cutting-edge

technique based on next-generation sequencing to detect and measure the amount of cfDNA in the total cell-free DNA present in the blood of solid organ transplant recipients has been recently introduced under the name AlloSure (CareDX, Brisbane, CA, USA) and is currently being validated for clinical use. In a prospective study on 65 heart transplant patients (565 samples), De Vlaminck et al. demonstrated that measuring cfDNA enabled the diagnosis of acute cellular rejection/ACR after heart transplantation by discriminating patients suffering rejection from the control group⁷⁰.

microRNA Profiling

A novel field in biomarker research aims to detect microRNAs, small non-coding RNA that regulate post-translational gene expression in cells, tissues or body fluids. A change in the microRNA profile during allograft rejection was first observed in 2009 by Anglicheau et al. in a study on renal transplant patients⁷¹. This study demonstrated changes in microRNA expression in renal allograft biopsies from 33 renal transplant recipients, and it was possible to distinguish rejection from non-rejection. When work on this thesis was initiated, no studies had been performed on the microRNA signature in either intragraft or peripheral blood of heart transplant patients.

Proximity Extension Assay

Emerging proteomic technology using proximity extension assay (PEA) has opened up the possibility of detecting new clinical biomarkers by performing simultaneous analysis of the large sets of circulating proteins in biological specimens with relatively small volumes⁷². Several biomarker studies on different pathological conditions have suggested that PEAs could offer a means of obtaining blood-based molecular fingerprints⁷³⁻⁷⁸. However, when work on this thesis began, this strategy had not been used in research on solid organ transplantation.

MicroRNA Biomarkers

MicroRNAs are a class of small (19-25 nucleotides in length), non-coding RNAs that bind to the 3' untranslated region (3'-UTR) of target messenger RNAs (mRNAs). Mature microRNAs can be associated with the RNA-induced silencing complex (RISC), which regulates gene expression by promoting mRNA degradation, or by inhibiting protein translation⁷⁹⁻⁸². Alternatively, microRNAs can be released from the cells into the circulation in the non-vesicle fraction by binding to RNA-binding proteins, such as Argonaute-2, or to lipoproteins, and in the vesicle fraction by incorporation into the extracellular vesicles⁸³⁻⁸⁵ (Figure 5).

A single microRNA has the ability to regulate hundreds of mRNAs by recognizing complementary sequences in their target mRNA, and multiple microRNAs can regulate an individual mRNA⁸⁶⁻⁸⁸. It has been reported in several studies that microRNAs play an essential role as fine-tuning regulators in the posttranscriptional regulation of gene expression in many pathophysiological processes associated with cardiovascular diseases⁸⁹⁻⁹³ and the modulation of both innate and adaptive immune responses⁹⁴⁻⁹⁷.

The presence of extracellular RNA in blood was first suggested in 2004⁹⁸. However, the first report of microRNA profiling in human plasma or serum was published in 2008^{99,100}. As microRNAs may be expressed in a tissue- or disease-specific manner, and the changes in their expression reflect pathophysiological conditions¹⁰¹⁻¹⁰³, their signatures in the blood can be used as potential non-invasive biomarkers for various diseases.




Figure 5. The mechanisms of release of microRNAs to the extracellular compartment. (Reprinted with permission from Nature Publishing Group. Guay C, et al. Circulating microRNAs as novel biomarkers for diabetes mellitus. *Nature reviews. Endocrinology*. Sep 2013;9(9):513-521.)

MicroRNAs in Liquid Biopsies

The use of circulating microRNAs has emerged as a non-invasive diagnostic biomarker strategy covering a wide range of pathological and biological processes^{104,105}. MicroRNA detection in a liquid biopsy, i.e. a liquid biomarker that can be isolated from body fluids such as blood, urine, pleural effusion, amniotic fluid, cerebrospinal fluid and ascites, is a rapidly expanding area of biomarker research due to its capacity to represent the tissue from which it originated¹⁰⁶⁻¹¹³. The level of extracellular microRNAs detected in liquid biopsy samples may show changes that are correlated to pathophysiological states^{114,115}, making these molecules excellent candidates for biomarkers of different biological and pathological conditions.

However, the technique is hampered by a number of problems, including low levels of RNA and high levels of RNA inhibitors in the body fluids, as well as the wide range of pre-analytical variables that increase its susceptibility. Despite these drawbacks, microRNAs have some properties that make them suitable for use in routine clinical practice, for example, they are remarkably stable in serum/plasma despite high ribonuclease activity, they are only minimally affected by pH changes and the freezing and thawing cycle, and their stability may be preserved for at least 40 years when frozen at -25°C ^{100,116-119}.

Intercellular Communication via microRNA Transport

A novel mechanism of intercellular communication that involves extracellular vesicles (EVs) has emerged over the past two decades. EVs are a heterogeneous subset of vesicles and, although there is a lack of standard nomenclature (it is still being defined by the EV research community^{120,121}), the current nomenclature is generally based on their size and mode of release from the cell of origin¹²².

Exosomes, with sizes ranging from 20 to 100 nm, are a subset of EVs with endosomal origin, formed intracellularly within multivesicular bodies, and released into the extracellular space via fusion of these multivesicular bodies with cell surface membrane¹²³. Ectosomes (or microvesicles) on the other hand, originate by direct budding from the plasma membrane^{124,125}. However, the term “exosomes” is most commonly used in the field of EV research to refer any type of EV¹²⁶, as there is no consensus or EV-specific marker that distinguishes the origin of EV subsets once they have been secreted from cells^{127,128}.

EVs are ubiquitous in body fluids¹²⁹⁻¹⁴² and can be recovered from conditioned cell culture medium¹⁴³⁻¹⁴⁵. According to the recommendations of the International Society for Extracellular Vesicles (ISEV), EVs may be isolated by a variety of techniques including ultracentrifugation, filtration, immunoaffinity isolation and microfluidics techniques¹⁴⁶.

The ability of most cell types, including immune cells, neurons, muscle cells and tumour cells, to secrete exosomes or microvesicles has been suggested in several studies¹⁴⁷⁻¹⁵³. Exosomes were first reported to transfer information between cells in a study on immune cells in 1998, and this study provided the basis of the hypothesis that exosomes could take an active part in intercellular communication¹⁵⁴. Later advances in proteomic analysis of exosome composition allowed researchers to demonstrate the selective intracellular protein content of exosomes, which allowed differentiation between exosomes and membrane vesicles released by apoptotic cells, providing insight into exosomes as a new type of intercellular messenger¹⁵⁵⁻¹⁵⁸.

However, the real breakthrough in the field of EVs came in 2007, when Jan Lötvall's group in Sweden reported the presence of microRNA and mRNA inside these vesicles¹⁵⁹. Their findings, together with subsequent studies showing that functional nucleic acids (microRNA, mRNA and other RNA species) can be shuttled in exosomes and regulate the recipient cell at a post-transcriptional level¹⁶⁰⁻¹⁶², have fundamentally shifted the paradigm concerning gene regulation.

Intercellular communication via microRNA transfer consists of 3 essential steps: 1) selection of microRNA shuttled in the appropriate EV carrier from the secreting cell; 2) protection of microRNA from circulating RNAses; and 3) the ability of microRNA to repress mRNA target in the recipient cells.

The first evidence of functional microRNA endogenous transfer was reported in 2009, when miR-126 was reported to be shuttled in apoptotic bodies targeting the RGS16 gene in cell-to-cell communication between endothelial cells¹⁶³. However, it was not until a study on functional miR-150 transfer via microvesicles between monocytes and endothelial cells in 2010 that the proposed microRNA-based communication network between immune cells and the vascular endothelium was demonstrated¹⁶⁴. Subsequent studies have unveiled a variety of "small-talk" involving functional microRNA transfer in both inflammatory and endothelial cells¹⁶¹.

Role of microRNA in Organ Transplantation

Discovered 24 years ago in *C.elegans*¹⁶⁵, microRNAs have been found to be involved in a wide range of cellular process, as well as playing important roles in regulating diverse functions in normal and diseased states, including transplant immunology. Most research on microRNAs in transplantation so far has concerned renal allografts.

MicroRNAs were first implicated as biomarkers of allograft status in a study on renal transplant patients, where it was found that the intragraft profile of microRNAs was changed in ACR patients compared to non-rejection patients⁷¹. In that study, miR-155 and miR-142 were among the microRNAs overexpressed in ACR compared to the controls. MiR-155 is one of the key players in the regulation of adaptive immunity and antibody-related T cell response¹⁶⁶. The expression of miR-142, a haematopoietic lineage-specific microRNA, depends on the activation state of the cells, and can be modulated by the differentiation of Th1 and Th2^{167,168}, the T-helper cell subsets that mediate graft rejection¹⁶⁹.

MiR-142-3p, a mature microRNA species generated from the 3' arm of the miR-142 stemloop, is closely associated with allograft rejection. The change in the miR-142-3p expression profile in biopsy samples from patients with ACR has been demonstrated in both humans and a transplantation animal model¹⁷⁰⁻¹⁷². The fact that miR-142-3p originates from immune cells, not from the graft tissue, raises the possibility of being able to predict rejection prior to organ damage.

Aims and Hypotheses

The overall objective of the work presented in this thesis was to investigate recent advances in genomic and proteomic techniques that could be utilized clinically for the non-invasive diagnosis and surveillance of allograft rejection after heart transplantation, as well as to investigate the biological role of microRNAs in the setting of ACR.

The specific aims and hypotheses of each study are given below.

Study I: The aim of this pilot study was to explore the possibility of using serum microRNAs as biomarkers of ACR after heart transplantation, by comparing serum microRNA profiles in samples collected before, during and after biopsy-proven rejection episodes in heart transplant patients with ACR.

Study II: In this validation study, the aim was to evaluate the levels of seven microRNAs that were found to be increased in serum during ACR in the previous pilot study, in a larger, independent cohort through collaboration with the Prevention of Organ Failure (PROOF) Centre of Excellence (Vancouver, Canada).

Study III: The aim of this study was to investigate the role of intercellular transfer of functional miR-142-3p between T cells and the endothelium in the setting of cardiac allograft rejection.

Study IV: In this study, the aim was to identify inflammatory fingerprints in the serum that could potentially be used as a non-invasive method of rejection surveillance for heart transplant patients with ACR, by profiling inflammation-related protein biomarkers.

Materials and Methods

This chapter provides a brief overview of the materials and methods, some of which are described in detail in the papers included in this thesis.

Heart Transplant Patients (Papers I, II, III and IV)

Subjects

The Lund cohort (Paper I)

All heart transplantations were performed at Lund University Hospital, Sweden. Serum samples from these patients were retrieved from the Microbiology Biobank at the hospital, and were matched in time with endomyocardial biopsy samples from the same patient. Informed consent was given by the patients in accordance with the recommendation and approval by the Regional Ethical Review Board in Lund. The patients included in the study represent different diagnoses (hypertrophic, dilated and ischaemic cardiomyopathy and congenital heart disease) and different age groups (13-69 years at transplantation). The diagnosis of ACR was made according to the ISHLT 1990 grading system in all patients. In 2004, a new ISHLT grading system was introduced to revise ISHLT 1990 grading system and the revised ISHLT 2004 classification has been used in clinical practice since.

The PROOF cohort (Papers II, III and IV)

All heart transplant recipients included in the studies described in Papers II, III and IV were enrolled in the Canadian Biomarkers in Transplantation Trial from 6 Canadian heart transplant centres (QE II Health Sciences Centre, Halifax, NS; Libin Cardiovascular Institute of Alberta, Calgary, AB; St. Boniface General Hospital, Winnipeg, MB; University of Ottawa Heart Institute, Ottawa, ON; Toronto General Hospital, Toronto, ON; St. Paul's Hospital, Vancouver, BC). The patients underwent heart transplantation between February 2009 and September 2013. Each local research ethics committee approved the study. A group of heart transplant patients with endomyocardial biopsy-verified ACR was compared with a control group of heart transplant patients without allograft rejection from the

same centre and within the same time period. All histological samples were blindly reviewed by three expert pathologists. Acute cellular rejection/ACR was defined according to the ISHLT 2004 classification.

Table 1. ISHLT Standardized Cardiac Biopsy Grading for Acute Cellular Rejection.

2004		1990	
Grade 0R	No Rejection	Grade 0	No Rejection
Grade 1R, Mild	Interstitial and/or perivascular infiltrate with up to 1 focus of myocyte damage	Grade 1, Mild	
		A - Focal	Focal perivascular and/or interstitial infiltrate without myocyte damage
		B - Diffuse	Diffuse infiltrate without myocyte damage
		Grade 2, Moderate (Focal)	One focus of infiltrate with associated myocyte damage
Grade 2 R, Moderate	Two or more foci of infiltrate with associated myocyte damage	Grade 3, Moderate	
		A - Focal	Multifocal infiltrate with myocyte damage
Grade 3 R, Severe	Diffuse infiltrate with multifocal myocyte damage ± edema, ± hemorrhage ± vasculitis	B - Diffuse	Diffuse infiltrate with myocyte damage
		Grade 4, Severe	Diffuse, polymorphous infiltrate with extensive myocyte damage ± edema, ± hemorrhage + vasculitis

Blood Collection (Papers I, II, III and IV)

Blood samples were collected in serum collection tubes and spun down in a refrigerated centrifuge within 2 hours to clot the blood and obtain clot-free serum supernatant. The serum was transferred to a sterile cryogenic vial and then aliquoted into smaller cryogenic vials. The aliquots of serum samples were stored frozen at -80°C until selected for biomarker analysis.

RNA Purification from Serum (Papers I and II)

Human blood serum is a challenging specimen type for RNA purification due to its high endogenous RNase activity and other pre-analysis variables such as red blood cell haemolysis and centrifugation conditions, which may interfere with the analytical process of microRNA measurement^{100,173}. For this reason, each step of the preparation and RNA extraction in serum samples must be specially optimized and delicately handled.

Total RNA, including small RNAs, was isolated using the miRNeasy Mini Kit (Qiagen) according to the manufacturer's instructions. In addition, MS2 carrier RNA (Roche) was added during the RNA purification steps in order to maximize the RNA yield and minimize the variation in purification variation¹⁷⁴. As the RNA yield from serum is very low, the RNA input was normalized by using equal volumes of serum, instead of using standard methods for the quantification of RNA concentration by 260 nm spectrophotometry (e.g. Nanodrop)¹⁷⁵.

RNA Purification from Serum Exosomes (Paper III)

The essential criterion to claim the presence of exosomes in the specimens is that they are isolated from extracellular fluids, including body fluids and secreting cells *in vitro*. Several strategies and techniques have been employed to isolate exosomes from extracellular fluids, and no consensus has so far been reached on the gold standard for RNA isolation from exosomes¹²⁶.

Most of the studies performed on exosomes from body fluids or culture medium have employed differential centrifugation with or without size filtration to isolate exosomes^{143,176-178}. Differential centrifugation was used in the study described in Paper III to pellet the following fractions, consecutively: cell debris/apoptotic bodies, larger EVs (microparticles/microvesicles/ectosomes) and exosomes. Total RNA, including small RNAs, was isolated from the pelleted exosomes obtained in the last centrifugation step using the miRNeasy Mini Kit.

First-strand cDNA Synthesis

First-strand cDNA synthesis was performed using the miRCURY LNA™ universal RT microRNA PCR kit (Exiqon) according to the manufacturer's protocol, where 8 µl of eluted serum RNA was used in 40 µl reverse transcription reactions. A synthetic RNA spike-in, UniSP6 CP, was added prior to cDNA synthesis as a control to monitor the variation in reverse transcription efficiency.

MicroRNA Profiling Assay (Paper I and Paper III)

The profile of microRNAs in serum may reflect blood cell activity¹⁷⁹, but the main challenge of profiling microRNA levels in the circulation is the low abundance of the microRNA fraction, which constitutes only a few percent of the total circulating RNA^{100,114}. To address this challenge, a high-sensitivity microRNA quantification platform must be used to quantify the microRNA level in the circulation^{173,180}. Previous studies have demonstrated that qRT-PCR-based platforms are the method of choice for microRNA profiling, due to their superior sensitivity and high specificity^{181,182}. In fact, qRT-PCR-based platforms have higher sensitivity than microarray-based platforms^{180,183}.

In the studies presented in Papers I and III, a qRT-PCR-based microRNA-profiling assay for 175 miRNAs, known to be present in human serum, was used. SYBR green-based qRT-PCR for microRNA expression profiling was performed using Serum/Plasma Focus Human microRNA PCR panels (Exiqon), according to the manufacturer's instructions. Seven reference gene candidates (miR-451, miR-16, miR-103, miR-425, miR-423-5p, miR-93 and miR-191) were included in the panel. A global mean expression normalization strategy was used due to the absence of a reference gene for the normalization of serum samples in this patient population, as has been described earlier¹⁸⁴.

Validation of Selected microRNAs (Paper I and II)

Individual qRT-PCR assays (Paper I)

Conventional qRT-PCR using LNATM microRNA primer sets (Exiqon) was performed to validate the results of the microRNA profiling assay in the serum samples (Paper I). PCR reactions were performed with cDNA synthesized in a different set of reactions from those used for the cDNA in the profiling experiment. Based on data from the profiling assay, miR-451 was selected as a suitable reference gene in the validation experiment, as it showed low inter-sample and inter-group variation. The relative expression was calculated using the $2^{-\Delta\Delta Ct}$ method¹⁸⁵.

Pick and Mix microRNA qRT-PCR panel (Paper II)

In order to assess the expression of seven microRNAs (miR-326, miR-142-3p, miR-101, miR-144, miR-27a, miR-424 and miR-339-3p), whose profiles were found to be changed in the first study, qRT-PCR reactions were performed using a Pick and Mix microRNA PCR Panel (Exiqon), according to the manufacturer's instructions. Although it is based on the same principle as the individual qRT-PCR validation assay, this panel is more convenient for quality control when handling a

large number of samples. The results obtained from the PCR panel were subsequently analysed using GenEx qPCR Data Analysis Software 2.0 (Exiqon). In brief, the raw data were normalized for run-to-run variations using UniSP3 IPC as an inter-plate calibrator. Delta Ct of (miR-23a-3p - miR-451) was used as a control for cellular contamination and haemolysis. Relative expression was calculated using the $2^{-\Delta\Delta Ct}$ method and uniSp6 spike-in was used as the reference for normalization.

Proteomic Profiling (Paper IV)

The PEA is a cutting-edge technique in biomarker research for proteomic profiling. This assay allows the analysis of 92 inflammation-related protein biomarkers using 1 μ l of serum simultaneously in 96 serum samples, or any other type of biofluid, as has been described previously^{72,186}.

In the study described in Paper IV, proteomic profiling in serum samples was performed at the Clinical Biomarkers Facility, Science for Life Laboratory, Uppsala University, Sweden, using The Olink Proseek® Inflammation 196 \times 96 multiplex immunoassay. Briefly, for each measured protein, a pair of highly specific antibody probes binds to the targeted protein, and if the two probes are in close proximity, a PCR target sequence is formed by a proximity-dependent DNA polymerization event. The resulting sequence is subsequently detected and quantified using qPCR (Figure 6).




Figure 6. The principle of the proximity extension assay (PEA). Pair-wise binding of probes (DNA oligo-labelled antibodies) that subsequently leads to the formation of a PCR target sequence by DNA polymerase in a proximity-dependent manner, resulting in a sequence that can be detected and quantified using standard real-time PCR.

In Vitro and *Ex Vivo* Cultures (Paper III)

Isolation of Human PBMCs and T cells

PBMCs and T cells were isolated from the blood samples of healthy volunteer donors. Informed consent of the donors included in this study was obtained prior to inclusion, and the study was approved by Lund University Ethics Committee, in accordance with US National Institutes of Health guidelines and the principles outlined in the Declaration of Helsinki.

In brief, the collected blood was centrifuged to obtain the buffy coats. PBMCs were isolated by centrifugation of the buffy coats on the top of Lymphoprep™ (Stemcell Technologies). T cells were isolated from PBMCs by depleting non-T cells to obtain pure and untouched T cells using the Dynabead™ Untouched Human T Cells Kit (Invitrogen) according to the manufacturer's instruction. The T cells obtained were then seeded in cell culture conditioned-medium.

***Ex vivo* Activation of Human T cells**

The function of human T cells can be assessed *ex vivo* by their ability to proliferate during T cell activation. Two different T cell activation methods were used. In the first method, 2% v/v PHA and 10 ng/μl IL-2 were added to the T cell culture medium to activate the T cells¹⁸⁷. This approach is less physiological than the second method, in which beads coated with anti-CD3 and anti-CD28 were used, in a manner that closely mimics the stimulation of the antigen-presenting cell¹⁸⁸.

Exosome Isolation

The exosome was isolated from the cell culture conditioned-medium using differential centrifugation. Briefly, the cell culture medium was centrifuged at 300 x g for 10 minutes to remove cell debris. The supernatant was then collected and centrifuged at 10,000 x g for 30 minutes to deplete large extracellular vesicles. Finally, the exosomes were pelleted by ultracentrifugation at 200,000 x g for 1 hour. All centrifugation was performed at 4°C. Both the exosome-containing pellets and the cell culture medium without exosomes (supernatant) were collected.

MicroRNA Transfer between T cells and Endothelial Cells

Human umbilical vein endothelial cells (HUVECs, Thermo Fischer Scientific) were used as an in vitro model of endothelial cells. Endothelial cells cultured in conditioned medium were stimulated with exosomes isolated from either serum samples from heart transplant patients with ACR or from activated T cells.

After 24 hours' incubation, stimulated endothelial cells were lysed in Qiazol, and RNA extraction was performed. Subsequently, qRT-PCR was performed for microRNA and mRNA analysis to evaluate the expression of miR-142-3p and its target gene, RAB11FIP1, respectively.

The second line of evidence of microRNA transfer in this study was provided by the blockage of transcription in endothelial cells. Briefly, endothelial cells were treated with 1 µg/ml of actinomycin D (Sigma). The cells were then maintained in culture for 24 hours in the presence or absence of T cell exosomes. MiR-142-3p transfer between T cell exosomes and endothelial cells was analysed by evaluating miR-142-3p expression in the endothelial cells.

Microarray of Endothelial cells

Microarray analysis was performed to predict the potential target of miR-142-3p. The RNA extracted from stimulated endothelial cells underwent quality control using an Agilent Bioanalyzer, and was analysed using the Affymetrix mRNA Gene 2.0 ST Array at the Swegene Center for Integrative Biology at Lund University. A significance analysis of microarray (SAM) *t*-test was performed to determine differentially expressed RNA. A cut-off value of >1.5 fold change and the bioinformatics tools TargetScan, miRanda, miRWalk and miRDB were used to identify potential targets of miR-142-3p

Transfection of Endothelial Cells

Cultured endothelial cells were transfected with 50 nM of either precursor or miR-142 mimic (Life Technologies) for 72 hours, according to the manufacturer's instructions. Scrambled pre-miRNA was used as a negative control. Subsequently, qRT-PCR analysis was performed on transfected cells to evaluate miR-142-3p expression. To confirm RAB11FIP2 as a target for miR-142-3p in endothelial cells on the protein level, the expression of RAB11FIP2 in HUVECs transfected with pre- and anti-miR-142 was evaluated using western blot analysis.

3'UTR Target Plasmid Reporter Assay

The interaction of target mRNA and miR-142-3p was analysed using miTarget miRNA 3'UTR target clones (Genecopoeia). The expression clones were based on the pEZX-MT51 vector containing dual reporter genes, while Gaussia luciferase (GLuc) served as microRNA 3'UTR target reporter, and secreted alkaline phosphatase (SEAP) served as an internal control for normalization of transfection efficiency and cell viability. A miTarget miRNA 3'UTR target clone, containing either of the nucleotides 1-2113 or 2018-4115 of the RAB11FIP2 3'-UTR, was co-transfected with 50 nM of precursor miR-142 (Life Technologies) or scrambled pre-miRNA as a negative control in HUVECs. An empty miTarget vector was transfected as a control. The transfection in HUVECs was performed using a Nucleofector device and its corresponding HUVEC Nucleofector Kit (Lonza). SEAP and GLuc activity were measured 72 hours after transfection using a Secrete-Pair Dual Luminescence Assay Kit (Genecopoeia) on a Glomax 20/20 Luminometer (Promega). Results were expressed as the ratio of GLuc to SEAP (Figure 7).




Figure 7 Inhibitory effect of miR-142-3p on the 3'UTR RAB11FIP2 clone expressed as the Gluc/SEAP dual reporter vector system. The 3'UTR RAB11FIP2 sequence is inserted downstream of the Gaussia luciferase (Gluc) reporter gene, which is driven by the SV40 promoter. The secreted alkaline phosphatase (SEAP) reporter, whose expression is controlled by the CMV promoter, is also cloned into the same vector and serves as internal control. The inhibitory effect of the mRNA-microRNA target interaction was analysed by measuring the reporter protein secreted by Gluc and SEAP activity.

Vascular Permeability Assay

The vascular permeability in the endothelial cells was evaluated in connection with knockdown of the RAB11FIP2 expression in the cells, as RAB11FIP2 has previously been shown to take part in the regulation of vascular endothelial barrier integrity and function¹⁸⁹. Briefly, endothelial cells were seeded on a fibronectin-coated insert of 24-well transwell plate (0.4 µm pore size; Corning). After siRNA-mediated knockdown of RAB11FIP2, 1 mg/ml/L fluorescein isothiocyanate FITC dextran (MW 70 kDa, Sigma) was added to the upper compartment of the transwell plate. The medium from the lower compartment was collected at different times, and the amount of FITC dextran that had passed into the lower compartment was measured with a plate reader (VICTOR3™, Perkin Elmer).

To provide the second line of evidence that miR-142-3p-containing exosomes may affect the vascular permeability in endothelial cells by targeting RAB11FIP2, exosome transfer in miR-142-3p-inhibited endothelial cells was analysed. Briefly, endothelial cells were cultured on the fibronectin-coated insert of a 24-well transwell plate. Cells were transfected with 50 nM of miR-142 inhibitor (Life Technologies) according to the manufacturer's instructions. After 72 hours' incubation, the cells were treated with activated T-cell exosomes for 24 hours, and subsequently harvested for qRT-PCR or vascular permeability assay analysis.

Statistical Analysis (Paper I - IV)

Statistical analysis was performed using GraphPad Prism 6.0 software (GraphPad Software Inc., San Diego, CA, USA) and SPSS Statistics v.22.0 (IBM Corp., Armonk, N.Y., USA). Visual inspection of the descriptive analysis of histogram and the D'Agostino-Pearson test were applied to test for the normality of the data and to detect a deviation from a Gaussian distribution in the sampled population. Parametric statistical analysis was used for normally distributed data, and the non-parametric approach was used for small sample sizes or non-normally distributed data. A *p*-value <0.05 was considered to indicate a significant difference.

To establish which diagnostic method gave the best combination of sensitivity and specificity, receiver operating characteristic (ROC) analysis was used to determine the cut-off points and to calculate the area under the curve (AUC).

To account for multiple testing in microarrays (Paper III), microRNA profiling assays (Papers I and III) and proteomic profiling (Paper IV), statistical analysis of microarrays (SAM) as described by Virginia Tusher¹⁹⁰, the Bonferroni correction, and the false discovery rate (FDR) method described by Benjamini and Hochberg¹⁹¹, were used respectively.

Results

Study I

Altered Serum microRNA Profiles during Acute Rejection after Heart Transplantation: Potential for Non-invasive Allograft Surveillance

A pilot study was conducted to explore the possibility of using serum microRNAs as biomarkers of ACR after heart transplantation, by comparing serum microRNA profiles in samples collected before, during and after histologically verified rejection in patients with cardiac allografts.

Circulating microRNA Profile was Altered during Acute Rejection

A good biomarker of acute cellular rejection should be able to detect small changes in the immune status of the patient before any damage has occurred to the allograft. To investigate whether such changes could be reflected by changes in microRNAs commonly found in human serum, a qPCR-based microRNA profiling assay was applied to 175 microRNAs known to be present in human serum. Ten patients who had experienced histologically verified rejections were selected, and temporally matched serum samples were analysed.

The patients included in this study represent different diagnoses (hypertrophic, dilated and ischaemic cardiomyopathy, and congenital heart disease) and different ages (13-69 years at transplantation). Serum samples were collected from each patient before any rejection had occurred (BR), during rejection (DR), and after rejection (AR) and analysed. The levels of seven microRNAs (miR-326, miR-142-3p, miR-101, miR-144, miR-27a, miR-424 and miR-339-3p) were found to be increased at least 1.5 times during rejection, compared to both before and after rejection.

Six Circulating Serum microRNAs are Significantly Increased During Rejection compared to Before Rejection

Conventional qRT-PCR was used to individually and technically validate the results obtained for the seven selected microRNAs after the initial screening for changes in serum microRNAs. Six microRNAs: miR-326, miR-142-3p, miR-101, miR-144, miR-27a and miR-424, were found to be significantly increased during rejection compared to before rejection (Figure 8).




Figure 8. MicroRNA profiling assay in heart transplant patients showing that the level of six microRNAs: miR-326, miR-142-3p, miR-101, miR-144, miR-27a and miR-424, increased significantly during rejection (DR), compared to before rejection (BR).

Evaluation of the Sensitivity and Specificity for miR-326 and miR-142-3p

ROC curves were used to evaluate the relationship between sensitivity and specificity for each microRNA when comparing levels before rejection to levels during rejection. MiR-326 and miR-142-3p showed notable AUC values of 0.86 and 0.80, respectively, which allowed significant discrimination between the normal and diseased state, as determined by histological examination (Figure 9).




Figure 9. ROC analysis of miR-326 and miR-142-3p showing area under the curve (AUC) values of 0.86 and 0.80, respectively.

Study II

Association of Serum miR-142-3p and miR-101-3p Levels with Acute Cellular Rejection after Heart Transplantation

The results from the pilot study were validated in a larger and independent cohort of heart transplant patients with biopsy-proven acute cellular rejection/ACR. The clinical characteristics of the patients were also evaluated in relation to the changes in level of circulating microRNAs.

Altered Circulating miR-142-3p and miR-101-3p Levels in the Serum of Heart Transplant Patients with ACR

There is consensus in the field of microRNA biomarker research that any clinical association regarding microRNA identified in a small sample of patients must be verified and validated in a larger, independent study.

In this study, seven circulating microRNAs (miR-326, miR-142-3p, miR-101, miR-144, miR-27a, miR-424 and miR-339-3p), whose profiles were changed in serum during ACR in the pilot study, were evaluated in a larger, independent cohort. Heart transplant patients with histologically verified ACR (n=26) were compared to a control group of heart transplant patients without allograft rejection (n=37) from the same centres and within the same time period. Detailed patient characteristics are listed in Table 2.

According to Student's *t*-test using $p=0.05$ as a cut-off value, the levels of all seven microRNAs were significantly higher in the heart transplant patients with ACR than in the patients with no rejection (NR). MiR-142-3p and miR-101-3p showed the most significant differences, with *p*-values of 0.0032 and 0.0041, respectively.

Table 2. Clinical characteristics of heart transplant patients included in Study II.

Patient Characteristics	Acute Cellular Rejection (n = 26)	Non Rejection (n = 37)	P-value
Recipient age (median, IQR <25-75>)	52 (37 - 61)	56 (45 - 61)	0.3
Recipient gender (male, n <%>)	17 (65)	29 (76)	0.3
ISHLT Biopsy Grade, n <%>			
- 0R (none)	-	37 (100)	
- 1R (mild)	2 (8)	-	
- 2R (moderate)	24 (92)	-	
Primary heart disease, n <%>			
- Ischemic cardiomyopathy	7 (27)	16 (42)	0.2
- Non-ischemic cardiomyopathy	14 (54)	21 (55)	0.9
- Valvular cardiomyopathy	2 (8)	0 (0)	0.08
- Congenital cardiomyopathy	1 (4)	1 (3)	0.8
- Miscellaneous	2 (8)	0 (0)	0.08
Time of Biopsy (Days after Tx) (median, IQR <25-75>)	23 (14 - 105)	37 (20 - 59)	0.09
Creatinine (mean, umol/L)	105.7	133.2	0.055

Circulating microRNA Levels in Serum Discriminate between Patients with ACR and Quiescence

ROC analysis was performed to evaluate the relationship between sensitivity and specificity based on the relative microRNA levels in cases of ACR and controls. All seven microRNA tested could be used to discriminate significantly between ACR and NR (Figure 10). However, according to the ROC analysis, miR-142-3p and miR-101 have the best diagnostic ability among the seven microRNAs tested, with AUC values of 0.78 and 0.75, respectively.




Figure 10. ROC analysis of the seven microRNAs investigated in Study II.

Circulating miR-142-3p and miR-101-3p Levels Reported by Time Post-transplantation

Serum microRNA levels were analysed at the same points in time that typical post-heart transplantation surveillance biopsies are performed, i.e. <1 month, 1-3 months, 3-6 months and 6-12 months after transplantation. The serum level of miR-142-3p was significantly higher in ACR patients than in NR patients in samples collected within 6 months post-transplantation. On the other hand, the serum level of miR-101-3p was significantly higher in the ACR group in samples taken during the first 3 months after transplantation, but not at later times (Figure 11).




Figure 11. Circulating miR-142-3p and miR-101-3p levels in serum according to time post-transplantation.

Correlation between Circulating miR-142-3p and miR-101-3p and Clinical Parameters

C-Reactive Protein

To investigate whether the changes in the levels of circulating miR-142-3p and miR-101-3p in the serum of heart transplant patients could be indicative of general inflammation, the correlation between these microRNA levels and C-reactive protein (CRP) was investigated. The results showed that there was no correlation between the level of CRP and the levels of miR-142-3p or miR-101-3p. Furthermore, there was no significant difference in CRP levels between the ACR and NR groups.

Immunosuppressive Drugs

Heart transplant recipients are subject to life-long treatment with a cocktail of immunosuppressive drugs to prevent allograft rejection. The aim of this study was to investigate whether the overall intensity of immunosuppression in the heart-transplanted patients could modulate the serum levels of miR-142-3p and miR-101-3p by analysing the correlation between the levels of calcineurin inhibitors, i.e. tacrolimus and cyclosporine, and miR-142-3p or miR-101-3p in the circulation of heart transplant patients. No significant differences were found between the levels of tacrolimus in the blood in ACR group and the NR group, and no correlations were seen between tacrolimus or cyclosporine levels with either miR-142-3p or miR-101-3p levels in serum.

Creatinine

Heart transplant patients that receive the calcineurin inhibitors cyclosporine and tacrolimus in immunosuppressant treatment are at a high risk of developing nephrotoxicity. To assess the relationship between circulating miR-142-3p and miR-101-3p levels and kidney function in heart transplant patients, the correlation between creatinine level and miR-142-3p and miR-101-3p was analysed. The results showed that there was no significant difference in creatinine levels in the ACR group compared to the NR group, and no correlation was found between either miR-142-3p or miR-101-3p and creatinine level.

Study III

Exosomal miR-142-3p is Increased during Cardiac Allograft Rejection and Augments Vascular Permeability through Downregulation of Endothelial RAB11FIP2 Expression

The study was carried out to investigate the role of exosomal transfer of functional miR-142-3p in cell-to-cell communication between T cells and the endothelium in the setting of cardiac allograft rejection.

MicroRNAs are Enriched in the Exosomes of Heart Transplant Patients with ACR

To analyse the exosomal microRNA content in the setting of ACR, qRT-PCR-based microRNA profiling was performed on exosomes isolated from serum of heart transplant patients. The profiling panel consisted of 175 microRNAs with high abundance in the circulation. Differences in microRNA expression were observed between the ACR group and the NR group. Moreover, miR-142-3p, miR-92a-3p, miR-339-3p and miR-21-5p were found to be enriched in exosomes from patients in the ACR group, compared to those in the NR group (Figure 12).




Figure 12. . Volcano plot showing microRNA fold change (ACR versus NR) based on microRNA profiling in exosomes extracted from the serum of heart transplant patients.

MiR-142-3p is Released upon In Vitro Activation of Human T cells

It was demonstrated in this study that miR-142-3p is expressed in human leukocyte subpopulations (monocytes, monocyte-derived macrophages, T cells and B cells); the highest expression being found in monocytes and T cells.

Considering the essential role of T cells in mediating the pathophysiological process of ACR, it was hypothesized that miR-142-3p, which was found to be enriched in the serum of heart transplant patients with ACR, might be shed from activated T cells to the extracellular compartment. Two distinct methods of in vitro activation of human T cells were performed, one using PHA/IL-2 stimulation and the other beads coated with anti-CD3 and anti-CD28 activation. The results showed that both T cell activation methods caused a release of miR-142-3p to the extracellular compartment. Moreover, a decrease was seen in the intracellular levels of miR-142-3p after both treatments (Figure 13).




Figure 13. Results of the two human T cell activation methods used in Study III.

Release of miR-142-3p from Activated T cells is Exosome-dependent

Given the novel method of cell-to-cell communication via exosomal transport of functional microRNA, it was hypothesized that the miR-142-3p in the extracellular compartment resulting from T cell activation is shuttled within the exosomes. Ultracentrifugation, the most widely utilized method for exosome isolation, was used to isolate exosomes from the supernatant of activated T cells. The level of miR-142-3p increased significantly in the exosome fraction after T cell activation, but not in the supernatant fraction. Moreover, inhibition of exosome biogenesis by pre-treating T cells with Brefeldin, an inhibitor of exosome formation, before T cell activation, caused complete inhibition of miR-142-3p release.

Endothelial Cells Can Take up miR-142-3p Released from Activated T cells

Given the recent evidence of an intercellular communication network between immune cells and endothelial cells, and that the pathophysiology of ACR is mainly orchestrated by T cells and endothelial cells, it was hypothesized that miR-142-3p shed by activated T cells via exosomes may be taken up by endothelial cells.

Several lines of evidences were provided to demonstrate the uptake of miR-142-3p by endothelial cells. Firstly, the expression of miR-142-3p was increased in endothelial cells treated with supernatant and in exosomes isolated from activated T cells, but not in the exosome-depleted supernatant. Secondly, the primary transcript of miR-142 (pri-miR-142) was also assessed in the stimulated endothelial cells to rule out endogenous expression. Thirdly, miR-142-3p expression was increased in the cells treated with T cell exosomes after the blockage of endothelial transcription by actinomycin D, which inhibits RNA synthesis.

MiR-142-3p Regulates RAB11FIP2 Expression in Endothelial Cells

MicroRNA is a fine-tuning regulator of gene expression that controls many physiological and pathological process. It was hypothesized that the uptake of miR-142-3p by endothelial cells would target a certain gene, leading to biological changes in endothelial cells. Microarray analysis was performed on endothelial cells treated with exosome-containing or exosome-depleted T cell supernatant to gain insight into the effect of the exosome-mediated uptake of miR-142-3p in endothelial cells on a transcriptome-wide level. *In silico* target gene prediction was subsequently employed using five different target prediction tools (miRanda, miRDB, miRWalk, RNA22 and TargetScan) to identify genes with a high probability of being true miR-142-3p targets. Finally, a literature search was conducted on genes predicted by three or more of the prediction tools, which overlapped with the exosome-regulated genes, to find candidate genes associated with vascular biology and thus potentially of importance in inflammation or graft rejection. As disruption of the function of the vascular endothelial barrier is a

molecular hallmark of inflammation as well as graft rejection, the study was focused on RAB11FIP2, which has previously been reported to play an important role in regulation of the endothelial barrier function (Figure 14).




Figure 14. *In vitro*, *in silico* and literature search for miR-142-3p target genes in Study III.

Interaction of miR-142-3p and RAB11FIP2 in Endothelial Cells Regulates Vascular Permeability

Given the recent evidence concerning the role of RAB11FIP2 in vascular permeability and the cellular mechanism of T cell-mediated cellular rejection being initiated by the increase in vascular permeability, it was hypothesized that the exosomal miR-142-3p shed by T cells upon activation and taken up by endothelial cells would interact with RAB11FIP2 and cause an increase in vascular endothelium permeability. First, siRNA-mediated knockdown of RAB11FIP2 expression in endothelial cells was performed, which resulted in an increase in endothelial permeability, providing evidence of a biological role of RAB11FIP2 in endothelial cells (Figure 15A). It was then demonstrated that inhibiting the transfer of miR-142-3p using the anti-miR (antagonist) of miR-142-3p could reverse the effect of exosome treatment on the permeability of endothelial cells (Figure 15B). Finally, a parallel rescue of RAB11FIP2 expression could be observed in endothelial cells pretreated with anti-miR-142 (Figure 15C).




Figure 15. The role of Rab11FIP2 and miR-142-3p in the regulation of endothelial permeability.

Study IV

Immunologic Serum Protein Profiles for Non-invasive Detection of Acute Cellular Rejection in Cardiac Allograft Patients

Recent advances in proteomics and genomics have led to the suggestion of several candidates as non-invasive biomarkers for the early detection of ACR in heart transplant recipients. The aim of this study was to explore the possibility of identifying inflammatory fingerprints in the serum of heart transplant patients with ACR, by profiling inflammation-related protein biomarkers using an emerging technique of proteomic profiling called the proximity extension assay (PEA).

Inflammatory Proteins Can Discriminate between Heart Transplant Patients with ACR and Quiescence

Based on the evidence that ACR of the cardiac allograft is mediated by T cells, it was hypothesized that T cell-associated proteins may be potential protein biomarkers that could be used to diagnostically discriminate between heart transplant patients with patients with ACR and those without. Proteomic profiling assays were performed on serum samples from heart transplant patients, and the results showed that 10 circulating serum proteins were increased in the ACR group, compared to the NR group. At least 7 of these 10 inflammatory biomarkers were T cell chemokines (CXCL9, CXCL10, CXCL11 and CCL19) or cytokines (SLAMF1, LTA and IL12B).

The FDR method was used to account for multiplicity in the protein profiling assay, in which 92 inflammatory proteins were measured simultaneously, and FDR-adjusted p -values (referred to as q values) below 0.05 were considered to indicate significant differences. Moreover, ROC analysis of the 10 protein biomarkers suggested that they could diagnostically discriminate between ACR and NR patients (Figure 16).

To determine independently informative predictors of ACR among the protein biomarkers that passed the FDR cut-off values, a stepwise logistic regression analysis with backward elimination was performed. This analysis constructs a final best-fit logistic regression model from protein biomarkers individually associated with rejection. CXCL10 and SLAMF1 were retained in the model with p -values of 0.001 and 0.006, respectively.




Figure 16. The expression of the 10 most significantly increased proteins in the serum of the ACR group and the NR group and their corresponding ROC curves.

A Multimarker Protein Score can be Constructed from CXCL10 and SLAMF1 Protein Biomarkers

In the context of ACR, it is very unlikely that a single protein biomarker will be able to discriminate between ACR patients and NR patients. Therefore, a multimarker protein score was constructed using CXCL10 and SLAMF1, the two protein biomarkers retained in the final logistic regression model. The multimarker protein score represents the cumulative NPX values of CXCL10 and SLAMF1 obtained from a comparison between the ACR and NR groups (Figure 17A). The performance of this multimarker protein score in identifying allograft rejection was evaluated using ROC analysis, and showed a notable AUC of 0.80 (Figure 17B).




Figure 17. Discrimination between ACR and NR groups using the multimarker protein score.

Discussion

The studies included in this thesis were concerned with two distinct topics of ACR. In Studies I, II and IV, the clinical aspects of molecular biomarkers, i.e. microRNAs and inflammatory proteins, were evaluated to investigate their potential as non-invasive biomarkers after heart transplantation. In Study III, the molecular aspects of acute cellular rejection were assessed by evaluating the functional role of extracellular microRNA and its involvement in vascular permeability, a molecular hallmark of ACR.

Non-invasive Rejection Surveillance – An Unmet Need

Heart transplantation remains a life-saving option for both adults and children with end-stage heart disease in the absence of contraindications^{192,193}. Over the past 5 decades, heart transplantation has evolved into a cornerstone therapy for heart failure patients with an excellent outcome, mostly due to advances in surgical techniques, peri-operative care and life-long treatment with immunosuppressant¹⁹⁴. Unlike other types of solid organ transplantation, such as kidney¹⁹⁵ or liver¹⁹⁶, where a slim possibility of clinical operational tolerance could be expected – defined as life-long stable and acceptable graft function without the need of immunosuppressants – this is not the case in heart transplantation. ACR, which requires immunosuppressants to prevent or treat, would be a lifetime impending threat for heart transplant recipients. Therefore, developing biomarkers matter in heart transplantation and has been a long-standing challenge, not only due to the imprecision of current methods to identify acute cellular rejection, but also for the heart transplant clinician to predict the risk of infection and patient prognosis, as well as to manage the immunosuppressant therapy required for every transplant patient.

Diagnostic advances in the field of heart transplantation have led to the development of endomyocardial biopsy techniques that can be used to diagnose ACR and to obtain endomyocardial biopsy specimens for surveillance. A system for the pathological grading of ACR was proposed by the ISHLT in 1990, and was revised in 2004³⁴. However, a number of drawbacks were associated with this

system. The three main issues concerning endomyocardial biopsy as a routine surveillance technique are its invasiveness, subjectivity and expense. These issues have prompted the development of a clinically validated, FDA-approved, gene-expression profiling test, known as AlloMap, to modulate the frequency of biopsy surveillance. However, AlloMap only partially addresses the need for a non-invasive post-heart transplantation method of diagnosis, and does not provide an equivalent alternative to endomyocardial biopsy. In a clinical study in which AlloMap-based surveillance was directly compared with endomyocardial biopsy-based surveillance (the IMAGE trial), the authors acknowledged the limitation of the study, as the patients enrolled had a low risk of rejection^{63,197}. Therefore, several efforts to identify new, reliable, non-invasive techniques are still on going in the biomarker research field and waiting to see the light of day.

Early Detection of ACR – Genomic Signatures

The development of a diagnostic assay for the early detection of ACR based on molecular changes in the cardiac allograft is a pressing medical need, as the diagnosis of ACR based on histopathological assessment is not always reliable. The subjectivity involved in evaluating the endomyocardial biopsy is one of the main drawbacks of the histopathological technique. Despite the effort to improve the concordance among the pathologists by revising the ISHLT 1990 classification¹⁹⁸ into a more simplified ISHLT 2004 classification³⁴, the discrepancies between the results are still common, with the overall agreement among pathologists being 70%³⁷.

Another significant drawback of histopathological assessment of endomyocardial biopsies in the management of heart transplant patients is that the method is not employed early enough to detect subclinical rejection prior to immune cell infiltration, which leads to graft damage. Being able to identify a rejection signature on the molecular level before histopathological and clinical signs of rejection become evident would be the ideal strategy (Figures 18).

Several methods of finding a molecular signature that can detect ACR earlier than histopathology assessment have already been studied, most of which rely on the microarray technique to characterize the gene expression profile associated with ACR. Horwitz et al. demonstrated that gene expression profiles in peripheral blood could be correlated with histologically verified cardiac allograft rejection⁶⁰. Hollander et al. described a biopsy-targeted blood biomarker discovery approach that could discriminate between patients with and without rejection¹⁹⁹. Holweg et al. identified both similarities and differences in intragraft gene expression compared to the 1990 ISHLT grading guidelines²⁰⁰. Li et al. investigated whether 10 genes, diagnostic of renal allograft rejection in blood, could be used to diagnose

and predict cardiac allograft rejection, and observed a common gene signature in renal and cardiac rejection that could diagnose and predict biopsy-proven rejection²⁰¹. However, it is only the developmental gene expression profiling study by Deng et al.⁶¹ (the CARGO study), followed by the clinical study by Pham et al.⁶³ (the IMAGE trial) that have made the journey from investigational status to regulatory approval of clinically relevant diagnostic test, called AlloMap.

The slow progress in heart transplantation biomarker research, despite vigorous efforts, reflects the complexity of ACR pathophysiology and the torturous path of discovery and validation of a biomarker, from the laboratory bench to clinical approval.




Figure 18. Timeline of allograft failure progression.

Circulating microRNAs as Non-invasive Biomarkers

Although circulating microRNAs are a relatively new platform in biomarker research, they have shown considerable promise^{104,115}. The biological information carried by circulating microRNAs may reflect the biological and pathological events in a gene expression network, given that one microRNA can regulate hundreds of mRNAs. However, the main reasons why microRNAs have generated such interest within the field of biomarkers across diverse pathophysiological states are because many pitfalls associated with molecular biomarkers can largely be avoided by using microRNAs, as they are much more stable than mRNA in serum/plasma, and they can be quantified with much greater sensitivity than proteins^{100,173}.

A good biomarker for allograft rejection will not only reduce healthcare costs and save patients unnecessary discomfort, but should also be able to identify risk patients at the time of transplantation, and thus predict rejection before the graft is damaged. Circulating microRNAs meet these key requirements. The key molecular properties of microRNAs, including their stability at room temperature, their ability to survive unfavourable physiological conditions (such as freeze-thawing cycles and extreme variations in pH), and the fact that they can be frozen for up to 40 years without any significant degradation^{100,117,118}, make them suitable for use in clinical practice where variations can be expected in the handling of samples. In addition, biomarker analysis should be easy and rapid. MicroRNA levels can be determined with qRT-PCR, a technique available at most clinical diagnostic laboratories. The cost of the analysis can therefore be expected to be reasonable, and the results could be obtained on the same day.

The first evidence of the potential of microRNAs as biomarkers in the field of solid organ transplantation was reported by Anglicheau et al., who demonstrated changes in the microRNA profile in biopsy samples from kidney transplant recipients⁷¹. However, this does not really satisfy the need for non-invasive rejection surveillance, as the microRNA signature used in their study was on the intragraft level. An attempt was made to address this issue in Study I by performing a pilot study to explore the possibility of detecting changes in the microRNA profile in peripheral blood during ACR. The levels of seven microRNAs in the serum of heart transplant patients were found to be significantly increased during ACR, compared to before and after rejection. Furthermore, two of these microRNAs, miR-142-3p and miR-326, could discriminate between ACR and non-rejection. Despite the small number of heart transplant patients included in Study I, the results indicated the possibility of using microRNA profiles as a new strategy to diagnose ACR after heart transplantation²⁰². In a subsequent study of 113 heart transplant patients, Van Huyen et al. showed that changes in the

expression of microRNAs occurring during ACR could be detected in serum, as well as in cardiac allograft tissue²⁰³, suggesting that changes in microRNAs in the peripheral blood reflect intragraft changes.

To identify clinically relevant and optimal biomarkers for ACR, it is essential to integrate information from multiple platforms, such as mRNA, microRNA and protein profiling²⁰⁴. Since AlloMap is limited in its ability to distinguish ACR from NR during the first 6 months post-transplantation⁶³ and is dependent on the time after transplantation⁶², it was deemed interesting to determine how microRNA levels react during ACR, regardless of the time after transplantation. The heart transplant patients included in Study II underwent endomyocardial biopsy surveillance according to the following schedule: every week in the first month, every 2 weeks between 1 and 3 months, once a month between 3 and 6 months and every 2 months between 6 and 12 months. The serum level of miR-142-3p was significantly higher in ACR patients than in NR patients during the first 6 months post-transplantation, which is the period during which the overall risk of rejection is highest. This suggests that the serum level of miR-142-3p may be useful in diagnosing ACR during the first 6 months after transplantation. However, the level of miR-101-3p was significantly higher in the ACR group than in the NR group only during the first 3 months post-transplantation.

Technical Considerations

Several issues must be addressed before serum microRNA levels can be used as a clinical diagnostic tool. Firstly, the appropriate microRNA profiling platform must be chosen. Three major microRNA profiling platforms are currently in use: microarray²⁰⁵⁻²⁰⁷, qRT-PCR-based method^{181,208} and RNA-sequencing^{209,210}. Although each platform has its own advantages and disadvantages, the method should allow transplant clinicians to make rapid and appropriate clinical decisions. Therefore, qRT-PCR appears to be a feasible option as it is relatively inexpensive and available in most clinical laboratories.

Secondly, the method of normalization used to compare microRNA levels in different samples using qRT-PCR must be considered. Despite microRNAs being very promising non-invasive candidate biomarkers in diverse molecular diagnostic applications, the normalization of extracellular microRNAs, including serum microRNAs, remains challenging. Considering the low microRNA yield in the serum (0.1-1 ng/ml)²¹¹, normalization to give the exact quantities of microRNAs is essential. There are several well-established protocols for the normalization of gene expression measurements using housekeeping genes that can be implemented in cellular microRNA. However, there are currently no known or established

housekeeping genes that can be used for the normalization of extracellular microRNA.

Nevertheless, several approaches for the normalization of circulating microRNA levels have been suggested, such as the normalization of serum microRNA expression by input volumes using equal amounts of serum in all samples. This approach has been challenged by the fact that there are considerable variations in RNA quantities extracted from equal volumes of serum from different individuals. Normalization by synthetic RNA Spike-in has also been used to monitor technical variations in RNA purification, cDNA synthesis and qRT-PCR steps. However, RNA spike-in has a limited ability to control the biological variation in the overall serum microRNA expression levels between different individuals. Global mean normalization has also been suggested to be a sensitive and accurate approach for high-throughput microRNA profiling²¹². This method may prove to be the best strategy for clinical samples due to its high appreciation to technical and biological variations of samples.

Intercellular Transport of Functional microRNAs

Extracellular microRNAs are ubiquitous in a diverse range of biological fluids, and are relatively stable, and thus have considerable potential as disease biomarkers and novel therapeutic agents. It has been long believed that intercellular communication takes place through the secretion of soluble molecules, i.e. the paracrine and endocrine mechanisms, or by cell-to-cell contact. The knowledge that functional microRNAs can be selectively transferred using cellular machinery to target gene expression in the recipient cells and alter the cellular phenotype, has led to a new understanding of cell-to-cell communication, and has fundamentally changed the concept of gene regulation.

Immune cells are communication experts that have the ability to convey their messages to each other via genetic information carried by extracellular vesicles during immune response²¹³. T cells play an essential role in many facets of immune response. It has been shown that T cell activation causes the secretion of extracellular vesicles²¹⁴, and that T cell interactions with B cells²¹⁵ or dendritic cells (DCs)²¹⁶ result in increased exosome release. Moreover, T cell exosomes undergo preferential sorting of their microRNA content before being transferred to the recipient cells²¹⁷, which is in line with the findings in Study III, where enrichment of selected microRNAs was observed in the serum exosome profiles of heart transplant patients with ACR, compared to those without.

Endothelial and T cells ”Small Talk” via Exosomes during ACR

Disruption of the function of the vascular endothelial barrier function is a molecular hallmark of inflammation, including graft rejection. During allograft rejection, endothelial cells advance the recruitment and the activation of alloreactive T cells^{23,24}. The accumulation of inflammatory infiltrates, mainly comprised of T cells, in the allograft is initiated by the inflammatory reaction of endothelial cells, which results in an increase in vascular endothelial permeability, leading to endothelial cell death and graft destruction²¹.

The role of endothelial cells in the context of organ transplantation has been examined in several studies using HUVECs experimental models²¹⁸⁻²²⁰. A similar experimental model was used in Study III to investigate the intercellular communication between endothelial cells and T cells that involves the transfer of miR-142-3p, a haematopoietic-tissue-specific microRNA that is highly expressed in T cells and has been implicated in several solid organ transplantation studies^{170-172,203}.

The study revealed that in the setting of acute cardiac allograft rejection, activated T cells communicate with endothelial cells via circulating miR-142-3p carried by T cell exosomes. In the recipient cells, miR-142-3p regulates the expression of RAB11FIP2 and promotes changes in endothelial physiology by impairing vascular integrity.

Although the findings of this study have shed some light on the molecular mechanism behind endothelial cell and immune cell communication during ACR, several matters remain to be further investigated. The selection process of intracellular miR-142-3p shuttled in the activated T cell exosomes remains unknown.

In Study III, several microRNAs were found to be enriched in the serum exosomes during ACR. This could provide a good starting point to examine the involvement of these microRNAs in the pathophysiology of ACR, as well as their respective target genes. Moreover, it would be of great interest to examine the role of miR-142-3p in the progression of ACR and its involvement in graft destruction or tissue damage, as well as which miR-142-3p target genes are involved in the respective processes.

MicroRNAs as Therapeutic Targets

Possible roles of microRNAs in transplant immunology have been suggested in several studies: as therapeutic targets, biomarkers of allograft status, regulators of chronic rejection and organ fibrosis, as well as mediators of organ rejection²²¹. Apart from the potential of miR-142-3p as a biomarker for cardiac allograft status, it would also be of great interest to use knowledge concerning the involvement of miR-142-3p in the cellular mechanism of graft rejection as a starting point to develop a microRNA-based therapeutic agent that can modulate the immune response during ACR.

Growing evidence suggests that a new class of RNA therapeutics, i.e. microRNA modulators (such as antagomirs or anti-miRs), could have some advantages in the treatment of human diseases, despite a number of obstacles that must be overcome²²². In fact, several microRNA therapeutics indicated for a wide range of diseases are currently under preclinical and clinical developmental. The main advantage of microRNA therapeutics is that they enable specific targeting of microRNAs and their respective downstream gene networks *in vivo*, thus influencing the underlying mechanisms of disease and disease progression.

In one of the studies using antimiR, a chemically engineered oligonucleotide to silence endogenous microRNAs, it has been showed that blocking miR-21 expression in a mouse model could inhibit the development of fibrosis in cardiovascular disease. Fibrosis is an endpoint of many pathological conditions, including ACR. The findings of that study, together with the increasing observations of the direct mechanistic involvement of microRNAs in inflammation and transplant immunity, suggest that microRNAs have the potential for clinical use as therapeutic tools, apart from their diagnostic and prognostic features in transplantation medicine.

Serum Protein Biomarkers – Tackling the Challenges

Serum or plasma is the logical choice for the discovery of a new biomarker to reach the ultimate goal of developing a simple blood test. More than 100 assays for different proteins in blood have been developed and are in routine use in clinical laboratories today. Human serum/plasma has been defined as the most comprehensive human proteome, and an appropriate circulating representation of all human tissues in biological or pathological states²²³. However, several challenges remain to be addressed in serum biomarker discovery in order to further development from bench to bed.

Although proteomic biomarker discovery shares many features and similarities with transcriptional profiling, the proteomic-based biomarker discovery in serum/plasma is more complex. Developing quantitative assay for biomarker candidates is the main bottleneck in proteomic biomarker discovery-validation pipeline²²⁴. It has been suggested that immunoaffinity capture addresses the issue of detecting and quantifying blood-borne protein biomarker candidates. However, there is evidence that this technique is unsuitable for true *de novo* discovery effort^{225,226}.

Efforts in proteomic-based biomarker discovery are also hampered by the very large range in the concentration of analytes that have to be detected and quantified in serum/plasma, and the absence of techniques to amplify them, as there is no PCR equivalent for protein²²⁷. In Study IV, an attempt was made to address the detection and amplification issues in proteomic-based biomarker discovery using PEA assay. This is a relatively new platform in proteomic profiling, in which two highly specific antibodies are used for each protein and the pair-wise binding of both antibodies to the target protein allows the formation of a PCR target sequence. This is extended using DNA polymerase and subsequently detected and quantified using qPCR, rendering great sensitivity and specificity to this approach. Given a comprehensive set of highly sensitive and specific protein assays that could be massively parallelized, the process of developing novel protein biomarkers using PEA assay is relatively straightforward.

Conclusions

The major conclusions drawn from the findings of the studies included in this thesis are given below.

- ❖ It is feasible to measure circulating microRNA levels in serum samples from heart transplant patients using a qRT-PCR-based microRNA profiling assay (*Study I*).
- ❖ The profile of circulating microRNAs is altered in serum samples from heart transplant patients during biopsy-proven ACR, compared to before and after rejection (*Study I*).
- ❖ The levels of seven microRNAs (miR-142-3p, miR-101-3p, miR-424-5p, miR-27a-3p, miR-144-3p, miR-339-3p and miR-326) were significantly higher in a cohort of heart transplant patients with ACR, than in a group of patients without ACR (*Study II*).
- ❖ The levels of miR-142-3p and miR-101-3p in serum can be used to discriminate reliably between patients with ACR and those without (*Study II*).
- ❖ MiR -142-3p is secreted into the extracellular compartment during ACR, as well as during in vitro activation of human T cells (*Study III*).
- ❖ MiR-142-3p shed by activated T cells can be taken up by endothelial cells, regulating the expression of RAB11FIP2 and promoting changes in endothelial physiology by impairing vascular integrity (*Study III*).
- ❖ Profiling the circulating inflammatory proteins in serum samples from heart transplant patients with ACR can help in the search for novel protein biomarkers that can be used to discriminate rejection from non-rejection (*Study IV*).
- ❖ Most of the circulating inflammatory fingerprints that show changes during ACR are associated with T cells (*Study IV*).

Acknowledgement

“Coincidence is God’s way of remaining anonymous”

(Albert Einstein)

I believe it is no coincidence that the people mentioned below have crossed my path during my PhD study, and I would like to express my gratitude to them all.

Cardiology

Jenny Öhman, MD, PhD. My Supervisor. Stepping into your office several years ago was one of the best things that ever happened to me. I am grateful to you for opening the door and letting me in to start my PhD research. Although you could not stay long, the door you opened to me has offered tremendous opportunities and created many memorable experiences, and for that I will be forever grateful and greatly indebted to you. Your scientific ideas have been an inspiration to me, and you are my role model, showing that it is possible to balance work and family life. I always enjoyed our wide range of discussion topics, from science, children, to the best sushi in town. An annual visit to your summerhouse is something my family and I look forward to every summer, and I sincerely hope we can keep up the tradition wherever life takes us to in the future. Thank you to keep holding my hands until the end of my PhD study!

Dr Olof Gidlöf. Having a talented musician as my mentor in the lab is probably one of the most interesting things that ever happened in my research life. I am grateful to you for always making time to share your knowledge and for stepping in as my supervisor in the last year of my study. I believe that our Cardiovascular Research paper is just a first step to begin the journey of thousand miles in your research career.

Professor David Erlinge. Head of the Department of Cardiology. Being part of a research group led by a successful clinician and brilliant scientist that everyone looks up to is a once-in-a-lifetime experience to me. I am grateful for all your support during my PhD.

Associate Professor Gustav Smith. It is not every day one has the opportunity to work with a great scientist, a “beautiful mind” who has vast knowledge in the clinical, molecular and statistical aspects of medical science. It has been such an honour to have that opportunity, and I am grateful for all your advice and guidance during my PhD study.

Associate Professor Oscar Braun. I am grateful for all your advice and guidance, as well as the time you spent during your busy night shifts gathering information about the Lund heart transplantation cohort for my study.

Dr Kristina Torngren. It has been a pleasure to work with you, and I am grateful for the time you spent gathering information on heart transplant patients when I started my study.

Monica Magnusson. I am grateful for your fantastic ability to quickly resolve every bureau-crazy issues I have encountered during my PhD study.

Rebecca Rylance. Thank you for lighting the candles in the long, dark tunnel of medical statistics in my study.

It has been such a pleasure to work alongside the following talented scientists in Molecular Cardiology, past and present, on a daily basis.

Associate Professor Björn Olde. I am thankful for all of our fruitful scientific discussions and for opening my eyes about a very important life lesson: Sometimes one has to lose the small battles in order to win the war.

Dr Chanyuan Tan. Thank you for your guidance in cell culture work when I started my study.

Selvi Celik. I will always be grateful to you for lending me a hand during critical paper-revision period of my PhD study. If there is anything you should not worry about, it is your future in research, because I am certain you will have a bright one.

Dr Ramasri Sathanoori. Your passion in science has always been fascinating. I wish you the best of luck in your future plans.

Dr Mardjaneh Karbalaee, Paulina Bryl-Gorecka and Neha Pimpalwar. The new members of the group. I wish you the best of luck in your research work.

I would also like to acknowledge **Siv Svensson**, the soul of the lab, for your contributions to my work, from keeping up the steady flow of blood samples for my experiments, to taking care of my endothelial cells during my ‘VAB dagarna’.

I am also grateful to the medical students **Anna Karlsson** and **Viveca Meissler**, as well as the Biomedicine Master’s student **Wahed Zidan** for providing an extra pair of hands during the course of my PhD work.

Collaborators

I gratefully acknowledge the following team members of the Prevention of Organ Failure (PROOF) Centre of Excellence, Vancouver, Canada, for their contributions to Studies II, III and IV, and for spending time on revising the papers: **Dr Zsuzsanna Hollander, Dr Karen K Lam, Janet-Wilson McManus, Associate Professor Scott J Tebbutt, Professor Raymond T Ng, Professor Paul A Keown, Dr Robert W McMaster and Professor Bruce M McManus.**

Foundations

Some of the best moments during my PhD studies were presenting my work at international conferences. I gratefully acknowledge the following foundations for funding my conference trips.

Läkarsällskapet i Lund, for supporting my trip to the American College of Cardiology (ACC) 61st Annual Scientific Session, in 2012 in Chicago, USA, and the International Society for Heart and Lung Transplantation (ISHLT) 2014 meeting in San Diego, USA.

The Purine International Committee, for awarding me a travel grant to attend Purine 2012 in Fukuoka, Japan.

Maggie Stephens Stiftelse, for funding my trip to the American Transplant Congress (ATC) 2013 in Seattle, USA.

The Swedish Heart and Lung Foundation, for financing my trip to ATC 2016 in Boston, USA.

BMC Lund

BMC D12 is a wonderful research environment, which I am grateful to have been part of. I am grateful to everyone at BMC D12 who was involved in my research life during my PhD studies, both on a daily basis, and for activities such as Friday breakfasts and Christmas parties. I would like to acknowledge the members of following research groups at BMC D12, past and present: **Professor Bengt-Olof Nilsson, Professor Jonas Erjefält, Professor Per Hellstrand, Professor Gunilla Westergren-Thorsson, Professor Roland Andersson, Professor Karl Swärd, Professor Fredrik Leeb-Lundberg, Professor Lo Persson, Associate Professor Sebastian Albinsson, Associate Professor Ellen Tufvesson and Associate Professor Lena Uller.**

The most important lesson I have learnt during my time at the BMC is that “Research is finite, but friendship is for a lifetime”. I will forever be grateful that the following people ever crossed my path at the BMC.

Dr Mario Grossi. Thank you for being my 24-hour on-call buddy for cell culture emergencies. You (together with all the Italian delicacies you cooked for me) will always stay in my heart (and my tummy).

Dr Diana Dahan. Thank you for radiating your positive energy to everyone around you and for being such a wonderful friend.

Dr Xanthi Stachte. Thank you for your warm friendship and your sarcastic sense of humour, which always cheered me up.

Dr Suado Snina Abdillahi. My sister-in-arms. Thank you for being such a wonderful, kind-hearted and wise friend.

(I believe soon to be) Dr Mariam Bagher. Thank you for taking my mind off work during our twice-a-year Copenhagen shopping-therapy trips.

Dr Daniel Svensson. Thank you for your 1 million HUVEC cells during my last minute paper revision deadlines that have secured my way to dissertation.

My Family

Dr Basuki Endah Priyanto. Living under the same roof with a prodigy (if ever I know one) and a scientist/inventor who has over 50 patents to his name has been my daily dose of inspiration. Thank you for being my rock during this journey. Thank you for managing household activities and taking care of our children during my bizarre working hours. Thank you for convincing me to embark on our “Englishman in New York” adventure in Sweden. I love you to the infinity and beyond, Buzz!

Rafika Ida Mutia. My baby sister. One of the brightest young researchers in Ericsson Sweden, who always inspire me with her achievements, her caring-loving personality, and her strength. Thank you for being such a great sister.

Rafli AR and Cut Zulifatma. My beloved parents in Indonesia. Thank you for your love, for the best upbringing a child could ever wish for, and for all your prayers, which have helped me through the difficult times in my life.

I would also like to acknowledge my Indonesian brothers- and sisters-in-arms for their support: **Dr Windi Indra Muziasari, Dr Yusak Budi Susilo, Dr Patricia Yocie and Dr Dhany Saputra.** We made it to the finish line, guys!

Rayan and Mika. My heart. My sunshine. My air. My life. My everything. I dedicate this thesis to both of you, my beloved sons, so that when you grow up, whatever choices you make in life later on, know this... knowledge is power.

References

1. Cooper DK. Christiaan Barnard and his contributions to heart transplantation. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. Jun 2001;20(6):599-610.
2. Barnard CN. The operation. A human cardiac transplant: an interim report of a successful operation performed at Groote Schuur Hospital, Cape Town. *South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde*. Dec 30 1967;41(48):1271-1274.
3. Leaf A. Sounding board: The MGH trustees say no to heart transplants. *The New England journal of medicine*. May 8 1980;302(19):1087-1088.
4. Oyer PE, Stinson EB, Jamieson SW, et al. Cyclosporine in Cardiac Transplantation - a 2-1/2 Year Follow-Up. *Transplantation proceedings*. 1983;15(4):2546-2552.
5. Emery RW, Cork R, Christensen R, et al. Cardiac transplant patient at one year. Cyclosporine vs conventional immunosuppression. *Chest*. Jul 1986;90(1):29-33.
6. Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report--2007. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. Aug 2007;26(8):769-781.
7. Tonsho M, Michel S, Ahmed Z, Alessandrini A, Madsen JC. Heart transplantation: challenges facing the field. *Cold Spring Harbor perspectives in medicine*. May 2014;4(5).
8. Stehlik J, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report--2012. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. Oct 2012;31(10):1052-1064.
9. Grunnet N, Bodvarsson M, Jakobsen A, et al. Aspects of present and future data presentation in Scandiatransplant. *Transplantation proceedings*. Mar 2009;41(2):732-735.
10. Grunnet N, Asmundsson P, Bentdal O, et al. Organ donation, allocation, and transplantation in the Nordic countries: Scandiatransplant 1999. *Transplantation proceedings*. Jun 2001;33(4):2505-2510.
11. Dellgren G, Geiran O, Lemstrom K, et al. Three decades of heart transplantation in Scandinavia: long-term follow-up. *European journal of heart failure*. Mar 2013;15(3):308-315.
12. Costanzo MR, Dipchand A, Starling R, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. *The*

Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. Aug 2010;29(8):914-956.

13. Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult heart transplantation report--2006. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. Aug 2006;25(8):869-879.
14. Chinen J, Buckley RH. Transplantation immunology: solid organ and bone marrow. The Journal of allergy and clinical immunology. Feb 2010;125(2 Suppl 2):S324-335.
15. Krensky AM, Weiss A, Crabtree G, Davis MM, Parham P. T-lymphocyte-antigen interactions in transplant rejection. The New England journal of medicine. Feb 22 1990;322(8):510-517.
16. Sayegh MH, Turka LA. The role of T-cell costimulatory activation pathways in transplant rejection. The New England journal of medicine. Jun 18 1998;338(25):1813-1821.
17. Al-Lamki RS, Bradley JR, Pober JS. Endothelial cells in allograft rejection. Transplantation. Nov 27 2008;86(10):1340-1348.
18. Felix NJ, Allen PM. Specificity of T-cell alloreactivity. Nature reviews. Immunology. Dec 2007;7(12):942-953.
19. Liu Z, Sun YK, Xi YP, et al. Contribution of direct and indirect recognition pathways to T cell alloreactivity. The Journal of experimental medicine. Jun 01 1993;177(6):1643-1650.
20. Benichou G. Direct and indirect antigen recognition: the pathways to allograft immune rejection. Frontiers in bioscience : a journal and virtual library. May 15 1999;4:D476-480.
21. Briscoe DM, Sayegh MH. A rendezvous before rejection: where do T cells meet transplant antigens? Nature medicine. Mar 2002;8(3):220-222.
22. Fangmann J, Dalchau R, Sawyer GJ, Priestley CA, Fabre JW. T cell recognition of donor major histocompatibility complex class I peptides during allograft rejection. European journal of immunology. Jun 1992;22(6):1525-1530.
23. Briscoe DM, Alexander SI, Lichtman AH. Interactions between T lymphocytes and endothelial cells in allograft rejection. Current opinion in immunology. Oct 1998;10(5):525-531.
24. Denton MD, Geehan CS, Alexander SI, Sayegh MH, Briscoe DM. Endothelial cells modify the costimulatory capacity of transmigrating leukocytes and promote CD28-mediated CD4(+) T cell alloactivation. The Journal of experimental medicine. Aug 16 1999;190(4):555-566.
25. Valujskikh A, Heeger PS. Emerging roles of endothelial cells in transplant rejection. Current opinion in immunology. Oct 2003;15(5):493-498.
26. Taflin C, Favier B, Baudhuin J, et al. Human endothelial cells generate Th17 and regulatory T cells under inflammatory conditions. Proceedings of the National Academy of Sciences of the United States of America. Feb 15 2011;108(7):2891-2896.

27. Baraldi-Junkins C, Levin HR, Kasper EK, Rayburn BK, Herskowitz A, Baughman KL. Complications of endomyocardial biopsy in heart transplant patients. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. Jan-Feb 1993;12(1 Pt 1):63-67.
28. Dandel M, Hummel M, Meyer R, et al. Left ventricular dysfunction during cardiac allograft rejection: early diagnosis, relationship to the histological severity grade, and therapeutic implications. *Transplantation proceedings*. Sep 2002;34(6):2169-2173.
29. Yilmaz A, Kindermann I, Kindermann M, et al. Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance. *Circulation*. Aug 31 2010;122(9):900-909.
30. Copeland JG, Valdes-Cruz L, Sahn DJ. Endomyocardial biopsy with fluoroscopic and two-dimensional echocardiographic guidance: case report of a patient suspected of having multiple cardiac tumors. *Clinical cardiology*. Aug 1984;7(8):449-452.
31. Anderson JL, Marshall HW. The femoral venous approach to endomyocardial biopsy: comparison with internal jugular and transarterial approaches. *The American journal of cardiology*. Mar 01 1984;53(6):833-837.
32. Miller LW, Labovitz AJ, McBride LA, Pennington DG, Kanter K. Echocardiography-guided endomyocardial biopsy. A 5-year experience. *Circulation*. Nov 1988;78(5 Pt 2):III99-102.
33. Blomstrom-Lundqvist C, Noor AM, Eskilsson J, Persson S. Safety of transvenous right ventricular endomyocardial biopsy guided by two-dimensional echocardiography. *Clinical cardiology*. Jun 1993;16(6):487-492.
34. Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. Nov 2005;24(11):1710-1720.
35. Tan CD, Baldwin WM, 3rd, Rodriguez ER. Update on cardiac transplantation pathology. *Archives of pathology & laboratory medicine*. Aug 2007;131(8):1169-1191.
36. Zerbe TR, Arena V. Diagnostic Reliability of Endomyocardial Biopsy for Assessment of Cardiac Allograft-Rejection. *Hum Pathol*. Nov 1988;19(11):1307-1314.
37. Crespo-Leiro MG, Zuckermann A, Bara C, et al. Concordance among pathologists in the second Cardiac Allograft Rejection Gene Expression Observational Study (CARGO II). *Transplantation*. Dec 15 2012;94(11):1172-1177.
38. Hummel M, Muller J, Dandel M, Hetzer R. Surveillance biopsies in heart and lung transplantation. *Transplantation proceedings*. Aug 2002;34(5):1860-1863.
39. Yang HM, Lai CK, Gjertson DW, et al. Has the 2004 revision of the International Society of Heart and Lung Transplantation grading system improved the reproducibility of the diagnosis and grading of cardiac transplant rejection? *Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology*. Jul-Aug 2009;18(4):198-204.

40. Subherwal S, Kobashigawa JA, Cogert G, Patel J, Espejo M, Oeser B. Incidence of acute cellular rejection and non-cellular rejection in cardiac transplantation. *Transplantation proceedings*. Dec 2004;36(10):3171-3172.
41. Mehra MR, Uber PA, Uber WE, Park MH, Scott RL. Anything but a biopsy: noninvasive monitoring for cardiac allograft rejection. *Current opinion in cardiology*. Mar 2002;17(2):131-136.
42. Bhat G, Burwig S, Walsh R. Morbidity of endomyocardial biopsy in cardiac transplant recipients. *American heart journal*. Apr 1993;125(4):1180-1181.
43. Ragni T, Martinelli L, Goggi C, et al. Echo-controlled endomyocardial biopsy. *The Journal of heart transplantation*. Sep-Oct 1990;9(5):538-542.
44. Dandel M, Hummel M, Muller J, et al. Reliability of tissue Doppler wall motion monitoring after heart transplantation for replacement of invasive routine screenings by optimally timed cardiac biopsies and catheterizations. *Circulation*. Sep 18 2001;104(12 Suppl 1):I184-191.
45. Puleo JA, Aranda JM, Weston MW, et al. Noninvasive detection of allograft rejection in heart transplant recipients by use of Doppler tissue imaging. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. Feb 1998;17(2):176-184.
46. Mankad S, Murali S, Kormos RL, Mandarino WA, Gorcsan J, 3rd. Evaluation of the potential role of color-coded tissue Doppler echocardiography in the detection of allograft rejection in heart transplant recipients. *American heart journal*. Oct 1999;138(4 Pt 1):721-730.
47. Marie PY, Angioi M, Carreaux JP, et al. Detection and prediction of acute heart transplant rejection with the myocardial T2 determination provided by a black-blood magnetic resonance imaging sequence. *Journal of the American College of Cardiology*. Mar 01 2001;37(3):825-831.
48. Taylor AJ, Vaddadi G, Pfluger H, et al. Diagnostic performance of multisequential cardiac magnetic resonance imaging in acute cardiac allograft rejection. *European journal of heart failure*. Jan 2010;12(1):45-51.
49. Bourge R, Eisen H, Hershberger R, et al. Noninvasive rejection monitoring of cardiac transplants using high resolution intramyocardial electrograms: initial US multicenter experience. *Pacing and clinical electrophysiology : PACE*. Nov 1998;21(11 Pt 2):2338-2344.
50. Grasser B, Iberer F, Schreier G, et al. Computerized heart allograft-recipient monitoring: a multicenter study. *Transplant international : official journal of the European Society for Organ Transplantation*. Apr 2003;16(4):225-230.
51. Kowalski RJ, Post DR, Mannon RB, et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. *Transplantation*. Sep 15 2006;82(5):663-668.
52. Israeli M, Yussim A, Mor E, Sredni B, Klein T. Preceding the rejection: in search for a comprehensive post-transplant immune monitoring platform. *Transplant immunology*. Jul 2007;18(1):7-12.
53. Cabrera R, Ararat M, Soldevila-Pico C, et al. Using an immune functional assay to differentiate acute cellular rejection from recurrent hepatitis C in liver transplant

- patients. *Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society*. Feb 2009;15(2):216-222.
54. Israeli M, Ben-Gal T, Yaari V, et al. Individualized immune monitoring of cardiac transplant recipients by noninvasive longitudinal cellular immunity tests. *Transplantation*. Apr 27 2010;89(8):968-976.
 55. Reinsmoen NL, Cornett KM, Kloehn R, et al. Pretransplant donor-specific and non-specific immune parameters associated with early acute rejection. *Transplantation*. Feb 15 2008;85(3):462-470.
 56. Millan O, Sanchez-Fueyo A, Rimola A, et al. Is the intracellular ATP concentration of CD4+ T-Cells a predictive biomarker of immune status in stable transplant recipients? *Transplantation*. Aug 15 2009;88(3 Suppl):S78-84.
 57. Kobashigawa JA, Kiyosaki KK, Patel JK, et al. Benefit of immune monitoring in heart transplant patients using ATP production in activated lymphocytes. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. May 2010;29(5):504-508.
 58. Huskey J, Gralla J, Wiseman AC. Single time point immune function assay (ImmuKnow) testing does not aid in the prediction of future opportunistic infections or acute rejection. *Clinical journal of the American Society of Nephrology : CJASN*. Feb 2011;6(2):423-429.
 59. Rossano JW, Denfield SW, Kim JJ, et al. Assessment of the Cylex ImmuKnow cell function assay in pediatric heart transplant patients. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. Jan 2009;28(1):26-31.
 60. Horwitz PA, Tsai EJ, Putt ME, et al. Detection of cardiac allograft rejection and response to immunosuppressive therapy with peripheral blood gene expression. *Circulation*. Dec 21 2004;110(25):3815-3821.
 61. Deng MC, Eisen HJ, Mehra MR, et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. Jan 2006;6(1):150-160.
 62. Starling RC, Pham M, Valentine H, et al. Molecular testing in the management of cardiac transplant recipients: initial clinical experience. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. Dec 2006;25(12):1389-1395.
 63. Pham MX, Teuteberg JJ, Kfoury AG, et al. Gene-expression profiling for rejection surveillance after cardiac transplantation. *The New England journal of medicine*. May 20 2010;362(20):1890-1900.
 64. Kubo SH, Naftel DC, Mills RM, Jr., et al. Risk factors for late recurrent rejection after heart transplantation: a multiinstitutional, multivariable analysis. *Cardiac Transplant Research Database Group. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. May-Jun 1995;14(3):409-418.

65. Chitty LS. Use of cell-free DNA to screen for Down's syndrome. *The New England journal of medicine*. Apr 23 2015;372(17):1666-1667.
66. Norton ME, Wapner RJ. Cell-free DNA Analysis for Noninvasive Examination of Trisomy. *The New England journal of medicine*. Dec 24 2015;373(26):2582.
67. Lo YM, Tein MS, Pang CC, Yeung CK, Tong KL, Hjelm NM. Presence of donor-specific DNA in plasma of kidney and liver-transplant recipients. *Lancet*. May 02 1998;351(9112):1329-1330.
68. Gadi VK, Nelson JL, Boespflug ND, Guthrie KA, Kuhr CS. Soluble donor DNA concentrations in recipient serum correlate with pancreas-kidney rejection. *Clinical chemistry*. Mar 2006;52(3):379-382.
69. Garcia Moreira V, Prieto Garcia B, Baltar Martin JM, Ortega Suarez F, Alvarez FV. Cell-free DNA as a noninvasive acute rejection marker in renal transplantation. *Clinical chemistry*. Nov 2009;55(11):1958-1966.
70. De Vlaminck I, Valantine HA, Snyder TM, et al. Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection. *Science translational medicine*. Jun 18 2014;6(241):241ra277.
71. Anglicheau D, Sharma VK, Ding R, et al. MicroRNA expression profiles predictive of human renal allograft status. *Proceedings of the National Academy of Sciences of the United States of America*. Mar 31 2009;106(13):5330-5335.
72. Assarsson E, Lundberg M, Holmquist G, et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. *PloS one*. 2014;9(4):e95192.
73. Enroth S, Johansson A, Enroth SB, Gyllensten U. Strong effects of genetic and lifestyle factors on biomarker variation and use of personalized cutoffs. *Nature communications*. Aug 22 2014;5:4684.
74. Chen H, Zucknick M, Werner S, Knebel P, Brenner H. Head-to-Head Comparison and Evaluation of 92 Plasma Protein Biomarkers for Early Detection of Colorectal Cancer in a True Screening Setting. *Clinical cancer research : an official journal of the American Association for Cancer Research*. Jul 15 2015;21(14):3318-3326.
75. Wiklund K, Gransbo K, Lund N, et al. Inflammatory biomarkers predicting prognosis in patients with acute dyspnea. *The American journal of emergency medicine*. Mar 2016;34(3):370-374.
76. Lind L, Arnlov J, Lindahl B, Siegbahn A, Sundstrom J, Ingelsson E. Use of a proximity extension assay proteomics chip to discover new biomarkers for human atherosclerosis. *Atherosclerosis*. Sep 2015;242(1):205-210.
77. Moen A, Lind AL, Thulin M, et al. Inflammatory Serum Protein Profiling of Patients with Lumbar Radicular Pain One Year after Disc Herniation. *International journal of inflammation*. 2016;2016:3874964.
78. Molin CJ, Westerberg E, Punga AR. Profile of upregulated inflammatory proteins in sera of Myasthenia Gravis patients. *Scientific reports*. Jan 03 2017;7:39716.
79. Ambros V, Lee RC. Identification of microRNAs and other tiny noncoding RNAs by cDNA cloning. *Methods Mol Biol*. 2004;265:131-158.

80. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell*. Jan 23 2004;116(2):281-297.
81. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. *Genes & development*. Mar 01 2006;20(5):515-524.
82. Bartel DP. MicroRNAs: target recognition and regulatory functions. *Cell*. Jan 23 2009;136(2):215-233.
83. Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. *Proceedings of the National Academy of Sciences of the United States of America*. Mar 22 2011;108(12):5003-5008.
84. Creemers EE, Tijssen AJ, Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? *Circulation research*. Feb 03 2012;110(3):483-495.
85. Guay C, Regazzi R. Circulating microRNAs as novel biomarkers for diabetes mellitus. *Nature reviews. Endocrinology*. Sep 2013;9(9):513-521.
86. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. *Cell*. Dec 26 2003;115(7):787-798.
87. Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of microRNAs on protein output. *Nature*. Sep 04 2008;455(7209):64-71.
88. Selbach M, Schwanhaussner B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. *Nature*. Sep 04 2008;455(7209):58-63.
89. Thum T, Catalucci D, Bauersachs J. MicroRNAs: novel regulators in cardiac development and disease. *Cardiovascular research*. Sep 01 2008;79(4):562-570.
90. Rao PK, Toyama Y, Chiang HR, et al. Loss of cardiac microRNA-mediated regulation leads to dilated cardiomyopathy and heart failure. *Circulation research*. Sep 11 2009;105(6):585-594.
91. Small EM, Olson EN. Pervasive roles of microRNAs in cardiovascular biology. *Nature*. Jan 20 2011;469(7330):336-342.
92. Wilson KD, Hu S, Venkatasubrahmanyam S, et al. Dynamic microRNA expression programs during cardiac differentiation of human embryonic stem cells: role for miR-499. *Circulation. Cardiovascular genetics*. Oct 2010;3(5):426-435.
93. Hosoda T, Zheng H, Cabral-da-Silva M, et al. Human cardiac stem cell differentiation is regulated by a microcrine mechanism. *Circulation*. Mar 29 2011;123(12):1287-1296.
94. Gantier MP, Sadler AJ, Williams BR. Fine-tuning of the innate immune response by microRNAs. *Immunology and cell biology*. Aug-Sep 2007;85(6):458-462.
95. Lodish HF, Zhou B, Liu G, Chen CZ. Micromanagement of the immune system by microRNAs. *Nature reviews. Immunology*. Feb 2008;8(2):120-130.
96. Trotta R, Chen L, Ciarlariello D, et al. miR-155 regulates IFN-gamma production in natural killer cells. *Blood*. Apr 12 2012;119(15):3478-3485.

97. Sun Y, Tawara I, Zhao M, et al. Allogeneic T cell responses are regulated by a specific miRNA-mRNA network. *The Journal of clinical investigation*. Nov 2013;123(11):4739-4754.
98. El-Hefnawy T, Raja S, Kelly L, et al. Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics. *Clinical chemistry*. Mar 2004;50(3):564-573.
99. Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. *British journal of haematology*. May 2008;141(5):672-675.
100. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. *Proceedings of the National Academy of Sciences of the United States of America*. Jul 29 2008;105(30):10513-10518.
101. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. *Nature*. Jun 09 2005;435(7043):834-838.
102. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. *Proceedings of the National Academy of Sciences of the United States of America*. Feb 14 2006;103(7):2257-2261.
103. Rosenfeld N, Aharonov R, Meiri E, et al. MicroRNAs accurately identify cancer tissue origin. *Nature biotechnology*. Apr 2008;26(4):462-469.
104. Keller A, Leidinger P, Bauer A, et al. Toward the blood-borne miRNome of human diseases. *Nature methods*. Sep 04 2011;8(10):841-843.
105. Reid G, Kirschner MB, van Zandwijk N. Circulating microRNAs: Association with disease and potential use as biomarkers. *Critical reviews in oncology/hematology*. Nov 2011;80(2):193-208.
106. Duttagupta R, Jiang R, Gollub J, Getts RC, Jones KW. Impact of cellular miRNAs on circulating miRNA biomarker signatures. *PloS one*. 2011;6(6):e20769.
107. Cortez MA, Calin GA. MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. *Expert opinion on biological therapy*. Jun 2009;9(6):703-711.
108. Hanke M, Hoefig K, Merz H, et al. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. *Urologic oncology*. Nov-Dec 2010;28(6):655-661.
109. Park NJ, Zhou H, Elashoff D, et al. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. *Clinical cancer research : an official journal of the American Association for Cancer Research*. Sep 01 2009;15(17):5473-5477.
110. Lin J, Wang Y, Zou YQ, et al. Differential miRNA expression in pleural effusions derived from extracellular vesicles of patients with lung cancer, pulmonary tuberculosis, or pneumonia. *Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine*. Oct 14 2016.
111. Sun T, Li W, Li T, Ling S. microRNA Profiling of Amniotic Fluid: Evidence of Synergy of microRNAs in Fetal Development. *PloS one*. 2016;11(5):e0153950.

112. Malpass K. Neuro-oncology: MicroRNAs in CSF-biomarkers of brain cancers and disease activity. *Nature reviews. Neurology*. May 15 2012;8(6):297.
113. Tokuhisa M, Ichikawa Y, Kosaka N, et al. Exosomal miRNAs from Peritoneum Lavage Fluid as Potential Prognostic Biomarkers of Peritoneal Metastasis in Gastric Cancer. *PloS one*. 2015;10(7):e0130472.
114. Weber JA, Baxter DH, Zhang S, et al. The microRNA spectrum in 12 body fluids. *Clinical chemistry*. Nov 2010;56(11):1733-1741.
115. Gilad S, Meiri E, Yogev Y, et al. Serum microRNAs are promising novel biomarkers. *PloS one*. Sep 05 2008;3(9):e3148.
116. Grasedieck S, Scholer N, Bommer M, et al. Impact of serum storage conditions on microRNA stability. *Leukemia*. Nov 2012;26(11):2414-2416.
117. Rounge TB, Lauritzen M, Langseth H, Enerly E, Lyle R, Gislefoss RE. microRNA Biomarker Discovery and High-Throughput DNA Sequencing Are Possible Using Long-term Archived Serum Samples. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*. Sep 2015;24(9):1381-1387.
118. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. *Cell research*. Oct 2008;18(10):997-1006.
119. Keller A, Leidinger P, Gislefoss R, et al. Stable serum miRNA profiles as potential tool for non-invasive lung cancer diagnosis. *RNA biology*. May-Jun 2011;8(3):506-516.
120. van der Pol E, Boing AN, Harrison P, Sturk A, Nieuwland R. Classification, functions, and clinical relevance of extracellular vesicles. *Pharmacological reviews*. Jul 2012;64(3):676-705.
121. Gould SJ, Raposo G. As we wait: coping with an imperfect nomenclature for extracellular vesicles. *Journal of extracellular vesicles*. 2013;2.
122. Thery C. Exosomes: secreted vesicles and intercellular communications. *F1000 biology reports*. 2011;3:15.
123. Thery C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. *Nature reviews. Immunology*. Aug 2002;2(8):569-579.
124. Mathivanan S, Ji H, Simpson RJ. Exosomes: extracellular organelles important in intercellular communication. *Journal of proteomics*. Sep 10 2010;73(10):1907-1920.
125. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. *The Journal of cell biology*. Feb 18 2013;200(4):373-383.
126. Lotvall J, Hill AF, Hochberg F, et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. *Journal of extracellular vesicles*. 2014;3:26913.
127. Colombo M, Raposo G, Thery C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. *Annual review of cell and developmental biology*. 2014;30:255-289.

128. Shen B, Wu N, Yang JM, Gould SJ. Protein targeting to exosomes/microvesicles by plasma membrane anchors. *The Journal of biological chemistry*. Apr 22 2011;286(16):14383-14395.
129. Bard MP, Hegmans JP, Hemmes A, et al. Proteomic analysis of exosomes isolated from human malignant pleural effusions. *American journal of respiratory cell and molecular biology*. Jul 2004;31(1):114-121.
130. Caby MP, Lankar D, Vincendeau-Scherrer C, Raposo G, Bonnerot C. Exosomal-like vesicles are present in human blood plasma. *International immunology*. Jul 2005;17(7):879-887.
131. Perkumas KM, Hoffman EA, McKay BS, Allingham RR, Stamer WD. Myocilin-associated exosomes in human ocular samples. *Experimental eye research*. Jan 2007;84(1):209-212.
132. Asea A, Jean-Pierre C, Kaur P, et al. Heat shock protein-containing exosomes in mid-trimester amniotic fluids. *Journal of reproductive immunology*. Oct 2008;79(1):12-17.
133. Poliakov A, Spilman M, Dokland T, Amling CL, Mobley JA. Structural heterogeneity and protein composition of exosome-like vesicles (prostasomes) in human semen. *The Prostate*. Feb 01 2009;69(2):159-167.
134. Simpson RJ, Lim JW, Moritz RL, Mathivanan S. Exosomes: proteomic insights and diagnostic potential. *Expert review of proteomics*. Jun 2009;6(3):267-283.
135. Qazi KR, Torregrosa Paredes P, Dahlberg B, Grunewald J, Eklund A, Gabrielsson S. Proinflammatory exosomes in bronchoalveolar lavage fluid of patients with sarcoidosis. *Thorax*. Nov 2010;65(11):1016-1024.
136. Berckmans RJ, Sturk A, van Tienen LM, Schaap MC, Nieuwland R. Cell-derived vesicles exposing coagulant tissue factor in saliva. *Blood*. Mar 17 2011;117(11):3172-3180.
137. Keller S, Ridinger J, Rupp AK, Janssen JW, Altevogt P. Body fluid derived exosomes as a novel template for clinical diagnostics. *Journal of translational medicine*. Jun 08 2011;9:86.
138. Lasser C, Alikhani VS, Ekstrom K, et al. Human saliva, plasma and breast milk exosomes contain RNA: uptake by macrophages. *Journal of translational medicine*. Jan 14 2011;9:9.
139. Street JM, Barran PE, Mackay CL, et al. Identification and proteomic profiling of exosomes in human cerebrospinal fluid. *Journal of translational medicine*. Jan 05 2012;10:5.
140. Vlassov AV, Magdaleno S, Setterquist R, Conrad R. Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. *Biochimica et biophysica acta*. Jul 2012;1820(7):940-948.
141. VanWijk MJ, VanBavel E, Sturk A, Nieuwland R. Microparticles in cardiovascular diseases. *Cardiovascular research*. Aug 01 2003;59(2):277-287.
142. Rabinowits G, Gercel-Taylor C, Day JM, Taylor DD, Kloecker GH. Exosomal microRNA: a diagnostic marker for lung cancer. *Clinical lung cancer*. Jan 2009;10(1):42-46.

143. Thery C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. *Current protocols in cell biology*. Apr 2006;Chapter 3:Unit 3 22.
144. Lasser C, Eldh M, Lotvall J. Isolation and characterization of RNA-containing exosomes. *Journal of visualized experiments : JoVE*. Jan 09 2012(59):e3037.
145. Cantin R, Diou J, Belanger D, Tremblay AM, Gilbert C. Discrimination between exosomes and HIV-1: purification of both vesicles from cell-free supernatants. *Journal of immunological methods*. Sep 30 2008;338(1-2):21-30.
146. Witwer KW, Buzas EI, Bemis LT, et al. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. *Journal of extracellular vesicles*. 2013;2.
147. Skog J, Wurdinger T, van Rijn S, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. *Nature cell biology*. Dec 2008;10(12):1470-1476.
148. Rosell R, Wei J, Taron M. Circulating MicroRNA Signatures of Tumor-Derived Exosomes for Early Diagnosis of Non-Small-Cell Lung Cancer. *Clinical lung cancer*. Jan 2009;10(1):8-9.
149. Vrijssen KR, Sluijter JP, Schuchardt MW, et al. Cardiomyocyte progenitor cell-derived exosomes stimulate migration of endothelial cells. *Journal of cellular and molecular medicine*. May 2010;14(5):1064-1070.
150. Kuwabara Y, Ono K, Horie T, et al. Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. *Circulation. Cardiovascular genetics*. Aug 01 2011;4(4):446-454.
151. Lachenal G, Pernet-Gallay K, Chivet M, et al. Release of exosomes from differentiated neurons and its regulation by synaptic glutamatergic activity. *Molecular and cellular neurosciences*. Feb 2011;46(2):409-418.
152. van der Vos KE, Balaj L, Skog J, Breakefield XO. Brain tumor microvesicles: insights into intercellular communication in the nervous system. *Cellular and molecular neurobiology*. Aug 2011;31(6):949-959.
153. Renzulli JF, 2nd, Del Tatto M, Dooner G, et al. Microvesicle induction of prostate specific gene expression in normal human bone marrow cells. *The Journal of urology*. Nov 2010;184(5):2165-2171.
154. Zitvogel L, Regnault A, Lozier A, et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. *Nature medicine*. May 1998;4(5):594-600.
155. Thery C, Boussac M, Veron P, et al. Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. *J Immunol*. Jun 15 2001;166(12):7309-7318.
156. Thery C, Regnault A, Garin J, et al. Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73. *The Journal of cell biology*. Nov 01 1999;147(3):599-610.
157. Wolfers J, Lozier A, Raposo G, et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. *Nature medicine*. Mar 2001;7(3):297-303.

158. Mathivanan S, Simpson RJ. ExoCarta: A compendium of exosomal proteins and RNA. *Proteomics*. Nov 2009;9(21):4997-5000.
159. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nature cell biology*. Jun 2007;9(6):654-659.
160. Mittelbrunn M, Sanchez-Madrid F. Intercellular communication: diverse structures for exchange of genetic information. *Nature reviews. Molecular cell biology*. Apr 18 2012;13(5):328-335.
161. Boon RA, Vickers KC. Intercellular transport of microRNAs. *Arteriosclerosis, thrombosis, and vascular biology*. Feb 2013;33(2):186-192.
162. van der Grein SG, Nolte-t Hoen EN. "Small Talk" in the Innate Immune System via RNA-Containing Extracellular Vesicles. *Frontiers in immunology*. 2014;5:542.
163. Zernecke A, Bidzhekov K, Noels H, et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. *Science signaling*. Dec 08 2009;2(100):ra81.
164. Zhang Y, Liu D, Chen X, et al. Secreted monocytic miR-150 enhances targeted endothelial cell migration. *Molecular cell*. Jul 09 2010;39(1):133-144.
165. Lee RC, Feinbaum RL, Ambros V. The *C. elegans* heterochronic gene *lin-4* encodes small RNAs with antisense complementarity to *lin-14*. *Cell*. Dec 03 1993;75(5):843-854.
166. Thai TH, Calado DP, Casola S, et al. Regulation of the germinal center response by microRNA-155. *Science*. Apr 27 2007;316(5824):604-608.
167. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. *Science*. Jan 02 2004;303(5654):83-86.
168. Tili E, Michaille JJ, Calin GA. Expression and function of micro-RNAs in immune cells during normal or disease state. *International journal of medical sciences*. Apr 03 2008;5(2):73-79.
169. Strom TB, Roy-Chaudhury P, Manfro R, et al. The Th1/Th2 paradigm and the allograft response. *Current opinion in immunology*. Oct 1996;8(5):688-693.
170. Danger R, Pallier A, Giral M, et al. Upregulation of miR-142-3p in peripheral blood mononuclear cells of operationally tolerant patients with a renal transplant. *Journal of the American Society of Nephrology : JASN*. Apr 2012;23(4):597-606.
171. Asaoka T, Sotolongo B, Island ER, et al. MicroRNA signature of intestinal acute cellular rejection in formalin-fixed paraffin-embedded mucosal biopsies. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. Feb 2012;12(2):458-468.
172. Van Aelst LN, Summer G, Li S, et al. RNA Profiling in Human and Murine Transplanted Hearts: Identification and Validation of Therapeutic Targets for Acute Cardiac and Renal Allograft Rejection. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. Jan 2016;16(1):99-110.

173. Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: approaches and considerations. *Nature reviews. Genetics*. Apr 18 2012;13(5):358-369.
174. Blondal T, Jensby Nielsen S, Baker A, et al. Assessing sample and miRNA profile quality in serum and plasma or other biofluids. *Methods*. Jan 2013;59(1):S1-6.
175. D'Alessandra Y, Devanna P, Limana F, et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. *European heart journal*. Nov 2010;31(22):2765-2773.
176. Gyorgy B, Szabo TG, Pasztoi M, et al. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. *Cellular and molecular life sciences : CMLS*. Aug 2011;68(16):2667-2688.
177. Momen-Heravi F, Balaj L, Alian S, et al. Current methods for the isolation of extracellular vesicles. *Biological chemistry*. Oct 2013;394(10):1253-1262.
178. Livshits MA, Khomyakova E, Evtushenko EG, et al. Isolation of exosomes by differential centrifugation: Theoretical analysis of a commonly used protocol. *Scientific reports*. Nov 30 2015;5:17319.
179. Pritchard CC, Kroh E, Wood B, et al. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. *Cancer Prev Res (Phila)*. Mar 2012;5(3):492-497.
180. Jensen SG, Lamy P, Rasmussen MH, et al. Evaluation of two commercial global miRNA expression profiling platforms for detection of less abundant miRNAs. *BMC genomics*. Aug 26 2011;12:435.
181. Mestdagh P, Feys T, Bernard N, et al. High-throughput stem-loop RT-qPCR miRNA expression profiling using minute amounts of input RNA. *Nucleic acids research*. Dec 2008;36(21):e143.
182. Benes V, Castoldi M. Expression profiling of microRNA using real-time quantitative PCR, how to use it and what is available. *Methods*. Apr 2010;50(4):244-249.
183. Chen Y, Gelfond JA, McManus LM, Shireman PK. Reproducibility of quantitative RT-PCR array in miRNA expression profiling and comparison with microarray analysis. *BMC genomics*. Aug 28 2009;10:407.
184. D'Haene B, Mestdagh P, Hellemans J, Vandesompele J. miRNA expression profiling: from reference genes to global mean normalization. *Methods Mol Biol*. 2012;822:261-272.
185. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic acids research*. May 01 2001;29(9):e45.
186. Lundberg M, Eriksson A, Tran B, Assarsson E, Fredriksson S. Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood. *Nucleic acids research*. Aug 2011;39(15):e102.
187. Ceuppens JL, Baroja ML, Lorre K, Van Damme J, Billiau A. Human T cell activation with phytohemagglutinin. The function of IL-6 as an accessory signal. *J Immunol*. Dec 01 1988;141(11):3868-3874.
188. Trickett A, Kwan YL. T cell stimulation and expansion using anti-CD3/CD28 beads. *Journal of immunological methods*. Apr 01 2003;275(1-2):251-255.

189. Yan Z, Wang ZG, Segev N, et al. Rab11a Mediates Vascular Endothelial-Cadherin Recycling and Controls Endothelial Barrier Function. *Arteriosclerosis, thrombosis, and vascular biology*. Feb 2016;36(2):339-349.
190. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. *Proceedings of the National Academy of Sciences of the United States of America*. Apr 24 2001;98(9):5116-5121.
191. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate - a Practical and Powerful Approach to Multiple Testing. *J Roy Stat Soc B Met*. 1995;57(1):289-300.
192. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. *European journal of heart failure*. Aug 2012;14(8):803-869.
193. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Journal of the American College of Cardiology*. Oct 15 2013;62(16):e147-239.
194. Miniati DN, Robbins RC. Heart transplantation: a thirty-year perspective. *Annual review of medicine*. 2002;53:189-205.
195. Roussey-Kesler G, Giral M, Moreau A, et al. Clinical operational tolerance after kidney transplantation. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. Apr 2006;6(4):736-746.
196. Alex Bishop G, Bertolino PD, Bowen DG, McCaughan GW. Tolerance in liver transplantation. *Best practice & research. Clinical gastroenterology*. Feb 2012;26(1):73-84.
197. Jarcho JA. Fear of rejection--monitoring the heart-transplant recipient. *The New England journal of medicine*. May 20 2010;362(20):1932-1933.
198. Billingham ME, Cary NR, Hammond ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. *The International Society for Heart Transplantation. The Journal of heart transplantation*. Nov-Dec 1990;9(6):587-593.
199. Hollander Z, Lin D, Chen V, et al. Whole blood biomarkers of acute cardiac allograft rejection: double-crossing the biopsy. *Transplantation*. Dec 27 2010;90(12):1388-1393.
200. Holweg CT, Potena L, Luikart H, et al. Identification and classification of acute cardiac rejection by intragraft transcriptional profiling. *Circulation*. May 24 2011;123(20):2236-2243.
201. Li L, Khush K, Hsieh SC, et al. Identification of common blood gene signatures for the diagnosis of renal and cardiac acute allograft rejection. *PloS one*. 2013;8(12):e82153.
202. Sukma Dewi I, Torngren K, Gidlof O, Kornhall B, Ohman J. Altered serum miRNA profiles during acute rejection after heart transplantation: potential for non-invasive allograft surveillance. *The Journal of heart and lung transplantation : the official*

- publication of the International Society for Heart Transplantation. *Apr* 2013;32(4):463-466.
203. Duong Van Huyen JP, Tibile M, Gay A, et al. MicroRNAs as non-invasive biomarkers of heart transplant rejection. *European heart journal*. Dec 01 2014;35(45):3194-3202.
 204. Roedder S, Vitalone M, Khatri P, Sarwal MM. Biomarkers in solid organ transplantation: establishing personalized transplantation medicine. *Genome medicine*. Jun 08 2011;3(6):37.
 205. Barad O, Meiri E, Avniel A, et al. MicroRNA expression detected by oligonucleotide microarrays: system establishment and expression profiling in human tissues. *Genome research*. Dec 2004;14(12):2486-2494.
 206. Castoldi M, Schmidt S, Benes V, et al. A sensitive array for microRNA expression profiling (miChip) based on locked nucleic acids (LNA). *RNA*. May 2006;12(5):913-920.
 207. Nelson PT, Baldwin DA, Scearce LM, Oberholtzer JC, Tobias JW, Mourelatos Z. Microarray-based, high-throughput gene expression profiling of microRNAs. *Nature methods*. Nov 2004;1(2):155-161.
 208. Chen C, Ridzon DA, Broomer AJ, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. *Nucleic acids research*. Nov 27 2005;33(20):e179.
 209. Thomas MF, Ansel KM. Construction of small RNA cDNA libraries for deep sequencing. *Methods Mol Biol*. 2010;667:93-111.
 210. Ramsingh G, Koboldt DC, Trissal M, et al. Complete characterization of the microRNAome in a patient with acute myeloid leukemia. *Blood*. Dec 09 2010;116(24):5316-5326.
 211. Ichikawa M, Akiyama H. A combination of extraction reagent and DNA microarray that allows for the detection of global miRNA profiles from serum/plasma. *Methods Mol Biol*. 2013;1024:247-253.
 212. Mestdagh P, Van Vlierberghe P, De Weer A, et al. A novel and universal method for microRNA RT-qPCR data normalization. *Genome biology*. 2009;10(6):R64.
 213. Thery C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. *Nature reviews. Immunology*. Aug 2009;9(8):581-593.
 214. Blanchard N, Lankar D, Faure F, et al. TCR activation of human T cells induces the production of exosomes bearing the TCR/CD3/zeta complex. *J Immunol*. Apr 01 2002;168(7):3235-3241.
 215. Muntasell A, Berger AC, Roche PA. T cell-induced secretion of MHC class II-peptide complexes on B cell exosomes. *The EMBO journal*. Oct 03 2007;26(19):4263-4272.
 216. Nolte-'t Hoen EN, Buschow SI, Anderton SM, Stoorvogel W, Wauben MH. Activated T cells recruit exosomes secreted by dendritic cells via LFA-1. *Blood*. Feb 26 2009;113(9):1977-1981.
 217. Mittelbrunn M, Gutierrez-Vazquez C, Villarroya-Beltri C, et al. Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. *Nature communications*. 2011;2:282.

218. Epperson DE, Pober JS. Antigen-presenting function of human endothelial cells. Direct activation of resting CD8 T cells. *J Immunol.* Dec 15 1994;153(12):5402-5412.
219. Marelli-Berg FM, Hargreaves RE, Carmichael P, Dorling A, Lombardi G, Lechler RI. Major histocompatibility complex class II-expressing endothelial cells induce allospecific nonresponsiveness in naive T cells. *The Journal of experimental medicine.* Apr 01 1996;183(4):1603-1612.
220. LaGier AJ, Pober JS. Immune accessory functions of human endothelial cells are modulated by overexpression of B7-H1 (PDL1). *Human immunology.* Aug 2006;67(8):568-578.
221. Spiegel JC, Lorenzen JM, Thum T. Role of microRNAs in immunity and organ transplantation. *Expert reviews in molecular medicine.* Dec 08 2011;13:e37.
222. Li Z, Rana TM. Therapeutic targeting of microRNAs: current status and future challenges. *Nature reviews. Drug discovery.* Aug 2014;13(8):622-638.
223. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. *Molecular & cellular proteomics : MCP.* Nov 2002;1(11):845-867.
224. Whiteaker JR, Lin C, Kennedy J, et al. A targeted proteomics-based pipeline for verification of biomarkers in plasma. *Nature biotechnology.* Jun 19 2011;29(7):625-634.
225. Anderson NL. The roles of multiple proteomic platforms in a pipeline for new diagnostics. *Molecular & cellular proteomics : MCP.* Oct 2005;4(10):1441-1444.
226. Gulmann C, Sheehan KM, Kay EW, Liotta LA, Petricoin EF, 3rd. Array-based proteomics: mapping of protein circuitries for diagnostics, prognostics, and therapy guidance in cancer. *The Journal of pathology.* Apr 2006;208(5):595-606.
227. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. *Nature biotechnology.* Aug 2006;24(8):971-983.